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INTRODUCTION
Although the ‘Witness Seminar’ approach to the historical development of a field is looked
upon with suspicion by some historians, not in the least because of their concern that
scientists are unable to speak objectively about what they do, not to mention their flawed
memories, nevertheless it provides a view of scientific progress that can never be obtained
solely from archival material. The most successful examples of this genre usually reflect the
discussion of a time of major advance or controversy in a particular field, and the survival
of enough of its participants for long enough to cover the period adequately. These
requirements were both met in the present Seminar.
Up to the period just after the Second World War, virtually nothing could be done for
patients with leukaemia. The nitrogen mustards had been introduced as a by-product of the
horrors of the First World War but, although they had some modest effect in slowing the
course of lymphomas, they were not effective at all for the management of leukaemia.
However, in the 1940s an increasing understanding of the mechanisms of action of certain
agents required for blood production, notably folic acid, led to the development by the
pharmaceutical industry of the first anti-folate drugs, notably aminopterin (page 7). This
was first used to treat children with acute leukaemia by Sidney Farber in Boston, an event
that opened a new era for the management of leukaemia. The elegant work of Hitchings
and Elion on purine and pyrimidine metabolism led to another important therapeutic
agent, 6-mercaptopurine, the first drug to have any effect on adult leukaemia (page 48).
Further developments followed rapidly, notably the discovery that corticosteroids had some
effect, if short lived, in controlling some types of leukaemia, and then the appearance of
several completely different classes of drugs, notably derivatives of antibiotics produced by
fungi, particularly daunorubicin, and the vinblastine and vincristine alkaloids derived from
plants (page 15).
But although haematologists now had a series of drugs that were active against leukaemia,
this was only the beginning of the story. Given alone, most of them only allowed short-term
control of the disease, which nearly always regressed. There followed an active period of
clinical trials using single or multiple agents in different combinations (page 53). With each
successive trial, the prognosis for leukaemia, particularly the childhood leukaemias,
improved, and once methods became available for destroying leukaemic cells that were
hidden away in the nervous system, the dream of a genuine cure for childhood leukaemia
became a reality (pages 26 and 43). Although progress was slower in acute leukaemias in
adults, and in the chronic leukaemias, genuine progress was made. The way the field
developed during this period was an example of collaborative clinical research at its very
best. In the mid-1970s bone marrow transplantation was first introduced (page 17) and,
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again, learning how to use combinations of anti-leukaemia drugs, radiotherapy, and bone
marrow transplantation, further dramatic advances were made.
Most of the participants in this Witness Seminar lived through this extraordinary period of
development in the leukaemia field. Its successes depended not just on the development and
assessment of new drugs and their combinations, but on major improvements in diagnostic
haematology and the ability to tide patients through frightful periods of bone marrow
depression and the inevitable infections that followed. Although when the history of this
period is examined in detail it may be concluded that the primary lead in the remarkable
advances in treatment for leukaemia came from the USA, there is no doubt that the
contributions which are discussed by these participants were of seminal value in many areas.
Indeed, leukaemia research in the second half of the twentieth century should be viewed as
a field in which international participation and collaboration worked particularly well for
the benefit of patients.
Professor Sir David Weatherall FRS
Institute of Molecular Medicine, Oxford
ii
WITNESS SEMINARS: MEETINGS AND PUBLICATIONS1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine Group, as
part of the Academic Unit of the Wellcome Institute for the History of Medicine, to bring
together clinicians, scientists, historians and others interested in contemporary medical
history. Among a number of other initiatives the format of Witness Seminars, used by the
Institute of Contemporary British History to address issues of recent political history, was
adopted, to promote interaction between these different groups, to emphasize the potential
of working jointly, and to encourage the creation and deposit of archival sources for present
and future use. In June 1999 the Governors of the Wellcome Trust decided that it would be
appropriate for the Academic Unit to enjoy a more formal academic affiliation and turned
the Unit into the Wellcome Trust Centre for the History of Medicine at University College
London from 1 October 2000. The Wellcome Trust continues to fund the Witness Seminar
programme via its support for the Centre.
The Witness Seminar is a particularly specialized form of oral history, where several people
associated with a particular set of circumstances or events are invited to come together to
discuss, debate, and agree or disagree about their memories. To date, the History of
Twentieth Century Medicine Group has held over 30 such meetings, most of which have
been published, as listed on pages v–viii.
Subjects for such meetings are usually proposed by, or through, members of the Programme
Committee of the Group, and once an appropriate topic has been agreed, suitable participants
are identified and invited. These inevitably lead to further contacts, and more suggestions of
people to invite. As the organization of the meeting progresses, a flexible outline plan for the
meeting is devised, usually with assistance from the meeting’s chairman, and some participants
are invited to ‘set the ball rolling’ on particular themes, by speaking for a short period of time
to initiate and stimulate further discussion. 
Each meeting is fully recorded, the tapes are transcribed and the unedited transcript is
immediately sent to every participant. Each is asked to check their own contributions and
to provide brief biographical details. The editors turn the transcript into readable text, and
participants’ minor corrections and comments are incorporated into that text, while
biographical and bibliographical details are added as footnotes, as are more substantial
comments and additional material provided by participants. The final scripts are then sent
to every contributor, accompanied by forms assigning copyright to the Wellcome Trust.
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1 The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to Twentieth
Century Medicine published by the Wellcome Trust and the Wellcome Trust Centre for the History of Medicine
at University College London.
Copies of all additional correspondence received during the editorial process are deposited
with the records of each meeting in Archives and Manuscripts, Wellcome Library, London. 
As with all our meetings, we hope that even if the precise details of some of the technical
sections are not clear to the nonspecialist, the sense and significance of the events are
understandable. Our aim is for the volumes that emerge from these meetings to inform those
with a general interest in the history of modern medicine and medical science; to provide
historians with new insights, fresh material for study, and further themes for research; and to
emphasize to the participants that events of the recent past, of their own working lives, are
of proper and necessary concern to historians.
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Dr Tilli Tansey: The History of Twentieth Century Medicine Group was established by the
Wellcome Trust in 1990 to bring together scientists, clinicians, and historians who have a
common interest in the history of recent medicine. A particularly successful venture has
been that of these Witness Seminars, where we gather together people who have been
involved in particular events or discoveries, to discuss and debate amongst themselves in a
chairman-led discussion about the events that they have witnessed.
This meeting on leukaemia has been organized on behalf of the Group by my two
colleagues, Dr Daphne Christie and Sir Christopher Booth. We have had the detailed
professional advice of Sir David Weatherall and Professor John Goldman, and we are very
grateful to both of them. Unfortunately, Sir David Weatherall cannot be here today – his
plane to Vienna has been rescheduled and he couldn’t make it in time to be here for the first
two hours of the meeting. But we are delighted to have John Goldman here; he qualified in
medicine at Oxford and then in 1970, after a period in America, was enticed back to this
country by David Galton, whom we are also delighted to see at this meeting, to join the
newly founded Medical Research Council’s Leukaemia Unit at the Hammersmith Hospital.
John Goldman is now Chairman of the Department of Haematology at the Imperial
College School of Medicine, based at Hammersmith Hospital, and he is also Director of the
Leukaemia Research Fund’s Centre for Adult Leukaemia. He has undertaken extensive
research and has clinical experience in all aspects of leukaemia. We were delighted not only
to have his advice during the planning of this meeting, but we are particularly grateful to
him for spending the afternoon chairing this meeting. And so without further ado, I would
like to hand over to the Chairman. 
Professor John Goldman: Thank you very much, Tilli. Yes, you are right, it was indeed
1970. I was looking through some old papers recently and I came across this delightfully
written and personally typed letter from David Galton, asking me if I would agree – I had
already approached David Galton previously, but now he was making me a firm offer – to
come to the MRC Leukaemia Unit as it was then.1 He mentioned in this one paragraph
that the technology that was developing – still embryonic at that time – was the use of
1 Professor John Goldman wrote: ‘The Medical Research Council sought in 1966/67 to establish a specialist
centre to investigate and treat acute leukaemia in adults. They approached Professor John Dacie at the
Hammersmith and suggested that David Galton should be the first director. A clinical facility was then built at
the Hammersmith Hospital and laboratory space was made available at the Commonwealth Building of the
Royal Postgraduate Medical School. The first junior staff included Alexander Spiers, Daniel Catovsky and John
Goldman.’ E-mail to Dr Daphne Christie, 1 December 2002. Professor David Galton wrote: ‘In those years Sir
John Dacie and I had frequent meetings with Dr John Hay of the MRC (Head Office) and one, or several
officers from the then Ministry of Health. Together we planned every structural detail of the new Unit, and all
its fittings.’ Note on draft transcript, 19 February 2003. See MRC Annual Report April 1968–March 1969, and
April 1969–March 1970, pages 32 and 44 respectively. 
sloppy agar to look at myelopoiesis in vitro.2 That, of course, has become one of the major
tools of the experimental haematologist since then. We made a very minor contribution in
the field of experimental haematology in the 1970s. 
There are a few people whom we would like to have had in this room today, who for various
reasons couldn’t make it, but I think the majority of people we asked and would like to have
are here. Collectively there is here tremendous experience in the investigation,
characterization and biology of leukaemia, and many aspects of treatment. Quite clearly, we
couldn’t undertake a comprehensive review of the story of leukaemia in say the last 50 years,
which I think more or less would have covered everybody we invited, in one four-hour
session. We had to choose things partly in accordance with the available personalities and
the expertise of people who could come. I would now like to ask David Galton to say a few
words about the history of leukaemia in the twentieth century.
Professor David Galton: It’s difficult to know where to begin in a subject like this. Gordon
Piller, in a few minutes’ time, will say a little about the first happenings up to the early part of
the last century. What I would like to do is remind you of the way certain drugs came to be
developed, which were the forerunners of the whole set of drugs that we use today. I particularly
want to talk about the circumstances in which three so-called biological alkylating agents were
synthesized in the early 1950s at the Chester Beatty Research Institute (CBRI), which was the
research arm of the then Royal Cancer Hospital,3 under its Director, Alexander (later Sir
Alexander) Haddow. Haddow had worked for a number of years at the old research laboratories
of the Royal Cancer Hospital, under Sir Ernest Kennaway. Kennaway and his colleagues had
made a fantastic contribution, by purifying the single chemicals extracted from coal tar, and
finding many of these were hydrocarbons, some of which were powerfully carcinogenic and
some of which were not.4 Haddow became extremely interested in this very remarkable
circumstance that the chemical differences between some of the hydrocarbons that were
carcinogenic and those that were not, were minuscule. He saw this as a possible way of attacking,
at a very basic level, the problem of how normally growing cells changed their habit and became
malignant. I think that was his frame of reference throughout his years as Director of the CBRI. 
Leukaemia
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2 Pike B L, Robinson W A. (1970) Human bone marrow colony growth in agar-gel. Journal of Cell Physiology
76: 77–84.
3 The Chester Beatty Research Institute – Institute of Cancer Research, Royal Cancer Hospital. See Royal
Cancer Hospital, London. (1951) The Royal Cancer Hospital, Fulham Road, London 1851–1951: A short history
of the Royal Cancer Hospital prepared for the centenary, 1951. London: J B Shears & Sons. See also note 70.
4 See Bernard J. (1934) L’érythro-leucémie éxperimentale provoquée  par le goudron. Le Sang 8: 28–38. See also
Haddow A. (1974) Sir Ernest Laurence Kennaway FRS, 1881–1958: Chemical causation of cancer then and
today. Perspectives in Biology and Medicine 17: 543–588. Waller R E. (1994) 60 years of chemical carcinogens:
Sir Ernest Kennaway in retirement. Journal of the Royal Society of Medicine 87: 96–97. 
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5 See, for example, Haddow A, Robinson A M. (1937) Influence of various polycyclic hydrocarbons on growth rate
of transplantable tumours. Proceedings of the Royal Society of London 122: 442–476. Professor David Galton wrote:
‘This was the “credo” of the CBRI, and we all took it for granted.’ Note on draft transcript, 29 November 2002.
In the 1930s he made a very important observation, which became known as the ‘Haddow’
phenomenon, and this was that some chemically induced experimental tumours could be
made to regress by treating them with purified carcinogenic compounds, whereas the non-
carcinogenic compounds, which were very similar, and were apparently equally toxic, did not
cause regression.5 He saw something very fundamental here, namely that the underlying
process of carcinogenesis and this curious growth-inhibitory phenomenon were related. He
also thought they were related in a Darwinian sense, namely that these compounds that
proved to be carcinogenic were in fact themselves growth inhibitory, that they did something
that made a cell that just did not die, survive by adopting a new habit of growth, which was
malignant growth. It was not ordinary non-specific toxicity, because the non-carcinogenic
compounds that were generally toxic too did not cause inhibition of growth and they did not
cause cancer. That led him to a whole lot of further studies, which were the basis of the
Institute’s work for the next 25 years. The fact that you could get growth inhibition of a
malignant growth (an experimentally induced malignant growth), by introducing a chemical
with apparently specific properties suggested to him that there was therapeutic potential
here. That’s how he came to initiate a programme that went on for many years and that
involved many colleagues who were biochemists, organic chemists, radiobiologists, and
cytogeneticists in trying to work out a scheme for producing compounds that might be
growth inhibitory in human cancer. That was the way the programme began. 
I hope that John Stock, who is here, will be able to say more about this during the meeting,
because it was he who synthesized the drug melphalan, one of the three drugs that are still
in use today after 50 years, namely chlorambucil, melphalan and busulphan. That is
actually the basis on which these compounds were studied in the first instance.
Goldman: I think we should stick with that note for a moment. This meeting must cover drug
development to some extent, so I wonder whether John Stock would like to go on at this stage. 
Dr John Stock: When I got the offer to participate today, and it was very kind of the Centre
for the History of Medicine to invite me, I thought I would write down a few headings
about the development of antitumour drugs. Then I decided I didn’t know whether this
would do, because with the four or five minutes allowed it might turn out to be just a litany
of drugs, so I gave up that idea and maybe, as David Galton said, we can discuss some of
these things later on. 
While we are talking about the old Chester Beatty, I would say how fortunate I was  in 1952
to be taken on by Franz Bergel, to whom I had written. I didn’t know which way it would
Leukaemia
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6 Stock J. (1952) Experiments in the chemotherapy of tuberculosis. PhD thesis, University of London. 
7 Nitrogen mustard (then known by the code name HN2). See Ross W C J. (1962) Biological Alkylating Agents.
London: Butterworth.
8 The CRC Centre for Cancer Therapeutics. Dr John Stock wrote: ‘Professor Michael Jarman was Head of the
Chemistry department of the Institute of Cancer Research prior to his retirement in 1950.’ Note on draft transcript,
3 November 2002.
go, because he had been my external examiner in my PhD, and although I got through I
didn’t know whether he thought much of it.6 Anyway, he took me on and it was he who
suggested the development. He was interested in the possibility of sticking a nitrogen
mustard group onto an amino acid, and this was the origin of melphalan. We chose
phenylalanine because chemically that was more suitable. Also, Walter Ross’s work on
nitrogen mustards was confined to the aromatic nitrogen mustards, which were rather
milder in action than the aliphatic ones and HN2.7
At that time, under Alex Haddow, the Chester Beatty was a bit of a family firm really, and
there were no questions of grant applications and things like that then, so we had a fairly
free hand. 
I went to a valedictory symposium last week in honour of Michael Jarman, who had been
Head of the Chemistry section of what is now known as the Cancer Therapeutic
Department, I forget its actual name now.8 What interested me was that in this meeting the
people who have now risen up to be directing things, the professors these days, like the
policemen, get younger every year, and the place has obviously got a lot of brain power there
now – and it’s well funded. The chemistry we did is now rather old-hat. The new thing that
has taken over [which is new to me anyway but is certainly used in industry as well as in
academic situations] is called combinatorial chemistry, which means that you can produce
hundreds of compounds – dozens, hundreds – at the same time, by reaction on solid
support and by doing everything in one vessel. You also fish all these things out and then
you screen them. 
That’s important, but what sort of screen? I think the initial screens will probably be
enzymes, which means that one has to find enzymes that are relevant to tumour treatment.
That’s the big thing; it’s always been the big thing I suppose, to find something that will
replace the animal tumour and whether it will be found or not – the whole thing hinges on
that. So what is hoped is that many lead compounds, perhaps hundreds of lead compounds
will be produced and ways will be found of testing these on a very small scale; eventually
the good ones can be made on a bigger scale. That seems to be the direction in which it is
going. I would make that point, rather than talk about the old stuff, which would be rather
a lengthy business, I think.
Goldman: Just one question for my own edification. What was the involvement of Chester
Beatty himself with the Fulham Road? Why did he put his money into the Fulham Road
when he did? 
Stock: I can’t remember. 
Goldman: Because there must have been a lot of money involved by the then contemporary
standards.
Stock: I am sorry, I have forgotten the reason. I know he came round once – Chester Beatty
came round to the laboratory where I was – and he discussed painting walls. 
Professor Raymond Powles: Just a couple of anecdotes about Alex Haddow, who was an
extraordinary person. You had to meet him; he was bigger than life in every sense. He  was
head of the Chester Beatty when I was houseman to David Galton at the Fulham Road
Marsden in 1966. Alex was admitted with a very large diabetic ulcer on his leg that he had
kept secret because he thought it was cancer, which says much about the perceptions of
cancer in those days. He unfortunately went blind over the following few years, but wrote
two leading articles on the future of cancer research in the early 1970s.9 It is a tribute not
only to his knowledge of cancer but also to his wonderful gift of writing that in spite of
being blind he was able to start all of 50 new paragraphs with three different words. The
other nice story is that he would only ever go to the United States in a first-class suite on
the Queen Elizabeth. He said if it was important enough to go to the US, then it should be
on the Queen Elizabeth. 
Professor Victor Hoffbrand: The line of research at the Chester Beatty was making
alkylating agents,10 but meanwhile there were the antimetabolites and I just wondered if
David could remind us of whether this was at the same time or earlier. I know that Sidney
Farber’s was the first treatment of leukaemia with aminopterin.11 There were a whole
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different group of compounds that were discovered after folic acid. How did these drugs
relate to each other?
Galton: This was a fascinating development because Sidney Farber was one of three people
who had noticed a property of folic acid that had been synthesized, I think, in 1945.12 Is
that right? As soon as this was synthesized several people started treating patients with
leukaemia with it, and three of them, independently, noticed that it had an adverse effect.
One of them, who was a Dane, Jorgen Bichel, found that the leucocyte count went up after
the use of folic acid. Another one was somebody you know, Victor – Frank Bethell – who
made the same observation, and so did Sidney Farber.13 Sidney Farber had a colleague, Dr
Yella Subba Row,14 a biochemist, who made conjugates of folic acid and analogues. It was
soon found that some of these analogues had powerful antileukaemic properties and
roughly that’s how Sidney Farber got involved, I think, but Frank might correct me. In a
very short time he had treated 16 infants and children with acute leukaemia, and ten of
them went into very good remission.15 They didn’t survive long, but this was the first time
anything like it had happened.
Goldman: This is a topic that Gordon Piller has very nicely reviewed in his publication.16
Are you going to talk about methotrexate, Gordon?
Dr Gordon Piller: It was aminopterin, not methotrexate at first. Methotrexate was
introduced a couple of years later.17
Professor Frank Hayhoe: While we are talking about these antimetabolites, I might just tell
you a little story. In March 1956 I happened to have gone across to the US in the Queen
Elizabeth. Unlike Haddow I wasn’t in first-class – I was travelling steerage or something
rather like that. It cost me £120 return to New York. However, I was going to a meeting
that was held in Detroit at the Henry Ford Hospital. I had been invited by Joe Burchenal
to stay in his house in Connecticut before the meeting. Anyway, we got up very early in the
morning, at about half past five, to commute into New York to the Sloan Kettering
Institute. This was a time when the antimetabolites were thought to be winning the battle
against leukaemia. It was Burchenal’s unit that had carried out clinical trials with 6-
mercaptopurine (6-MP) and had published the first results in 1953.18 I had also written a
paper, which appeared in the Lancet in 1955, on the treatment of, I think, 15 patients with
acute myelogenous leukaemia (AML) with 6-MP.19
To revert to the Detroit affair, when we got to this conference there were copies of a
newspaper available on the table, possibly the New York Times, or some other widely read
paper. Across a huge double-page spread was a set of chemical formulae that depicted the
de novo synthesis of nucleic acids with about 50 different compounds en route, as it were.
This was presented to the readership under a heading that said ‘the one-two for leukaemia’
(this is a pugilistic term indicating ‘knockout’, I understand). The ‘one-two’ for leukaemia
was 6-MP and azaserine. Actually, azaserine subsequently disappeared, although
azathioprine got extensively used to prevent antibody formation at a later stage.20 However,
I am just going to get to the story. Somebody presenting a paper at this meeting put a slide
of this double-page spread from the newspaper up on the board and said: 
I wonder what proportion of the population of New York who read this paper would
actually be able to follow this? It reminds me of a story, of Mr Sargeant Sullivan in the
law courts, presenting a case on behalf of a labourer from Killarney, Southern Ireland,
who had sustained an injury of some kind, that didn’t occur during his work. The judge
became more and more testy and eventually said, ‘But Sargeant Sullivan, surely your
client must be aware that “de injuriis non in operibus, lex non curat”.’ Mr Sargeant
Sullivan hesitated for a moment and then said, ‘My lord, I understand that in Killarney
they talk of little else’. 
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However, to revert very briefly to the drug development that we are discussing, before this
meeting some of us were talking about John Wilkinson, who died aged 101, only a few
years ago. He had worked with the original nitrogen mustard (HN2) during the wartime
years and published work in 1947 on the use of this drug, not particularly in leukaemias,
although I think he did use it on some chronic myeloid leukaemias (CMLs), but
particularly in Hodgkin’s disease.21
Similarly there were early reports from the US along the same lines, leading to the work
done subsequently at the Chester Beatty on putting various attachments onto the nitrogen
mustard structure. We first started using these in Cambridge in about 1956 or 1957, when
we set up a clinic that we called a reticulosis clinic. One of the first drugs we used was
CB1348, which subsequently became named chlorambucil.22
Goldman: I think, Gordon, that some of the topics we have already touched upon you have
researched in detail. Would you like to continue? 
Piller: At the beginning of the twentieth century leukaemia was generally considered to be
a chronic disease, with arsenic being the only agent offering some relief.23 Dr George Dock24
of Ann Arbor (Michigan, USA) regularly prescribed arsenic to his patients with leukaemia
and the reason for him doing that, he said, was ‘that patients tended to get well, even
temporarily, when it was given whereas when other remedies were prescribed they did not’.
Osler, in 1914, commented that he had not seen any striking permanent improvement in
patients treated with X-rays.25 And, Wintrobe in 1945 stated, ‘There is no specific
treatment for leukaemia’;26 the therapeutic depression continued. Lionel Whitby’s critical
analysis delivered in 1951 in his presidential address to the Association of Clinical
Pathologists, which was echoed in the US, was that leukaemia then was regarded as a
dreaded disease which few, if any, survived.27 The urgent need for fresh viewpoints on the
nature of leukaemia and its therapy was now acknowledged, but these were to come from a
most unexpected source, chemical warfare. 
The use of mustard gas by the German forces in the First World War caused the allies in the
Second World War to take preventive measures in case mustard gas should be used again.
Secret research, both in the USA and here in Britain, on nitrogen mustards, the nitrogen
analogues of the gas, found that they produced marked changes in the haemopoietic system.
It was soon realized that nitrogen mustard (then known by the code name HN2) produced
an action on blood cells and bone marrow unlike any other known chemical substance. This
was the advent of chemotherapy.28
In the USA Cornelius P Rhoads headed the medical division of the US Chemical Warfare
Service, and recruited many investigators who, once discharged from their military duties,
became a formidable group of leaders in the early development of chemotherapy. Joe
Burchenal was one of them and I was very privileged, as Frank has also mentioned, to enjoy
his hospitality. I asked him what was in his mind when he and his colleagues were working
on nitrogen mustard. He said, ‘Well, there were six of us who were working in the Army at
that time on this, and we thought when we came out what we would do was to kick it
around a bit.’ So what he and his colleagues in New York did was seize any basement
laboratory that was going and they started on the transfer of their wartime research into
peaceful application. The Sloan Kettering Institute, which was opened in 1948, included an
Experimental and Clinical Chemotherapy Division that all those people were a part of.29
The other centres involved in America were Boston, Chicago and Salt Lake City. 
As a young man I was also privileged to have a Sunday morning meeting with Sidney Farber
in his laboratory in Boston. I asked him, because I was not employed by him, so it was easy
to put the question to him, ‘What has to be done to promote advances in the treatment of
leukaemia?,’ knowing of his work with folic acid with Subba Row as David has pointed
out.30 He said it was time that patients, particularly children, with leukaemia, were ‘entitled’
to remission, and added that that was his mission. This gives some idea of the thoughts that
were in the minds of the pioneers. 
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John Wilkinson was working in Britain at this time,31 and Frank Fletcher at Manchester. I met
John Wilkinson after his 98th birthday at his home and I asked him various questions, mostly
on leukaemia and other blood diseases. He was a bit of a character; he recognized little south
of Watford Junction, but fortunately by this time I had left London. Anyhow he was very
disappointed that because he was subject to the wartime Secrets Act,32 he couldn’t publish their
findings until 1947, when, of course, there were papers published earlier on work he was
involved in in Britain. He later reported on work he conducted from 1942 onwards on 18
cases, most of which were lymphomas, Hodgkin’s disease and one or two leukaemias.33
Also involved in early chemotherapy were Davidson in Edinburgh and a few people
elsewhere. It was Alexander Haddow who formed a major group at the CBRI in London.34
The earlier pioneers were not discouraged by the initial results of this new challenge in what
was essentially experimental medicine. Following this there was intensive cooperative work
by investigators in Britain and the USA to find preparations that were less toxic but with a
targeted effect on abnormal cells. This was achieved by chemical manipulation to improve
the therapeutic efficacy of the battle against leukaemia. David Galton, who has already
spoken, was one of those pioneers, leading clinical work as a member of Alexander
Haddow’s team; he contributed much in those early days to the success patiently achieved. 
The other point I would finish on is that, although it is sometimes recognized that the
Americans led the way in this, there was much effort going on in Britain too. Happily, there
was a lot of cooperation. 
Goldman: Any comments on what Frank and Gordon have said? If not, I think we will go
on and ask Derek Crowther to return to the beginning, as it were.
Professor Derek Crowther: I was asked to give a brief summary of the history of
leukaemia, which, of course, before this illustrious group I don’t wish to do particularly.
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But I thought that what I would do is just make some comment, taking on board the
comments that have already been made about the introduction of chemotherapy. Of
course, arsenic has been mentioned. Arsenic has been used for the treatment of malignancy
for 4000 years now. It was mentioned in the Ramayana, which is an Indian text and even
Hippocrates mentioned it. It has also been mentioned off and on, throughout the ages, as
being effective in the treatment of cancer. Lissauer was the first to use it in 1865 
for chronic leukaemia, but it has been used since, and is currently subject to 
renewed interest.35
Regarding the Haddow approach during the mid part of the twentieth century, in my
opinion he was the father of modern chemotherapy. He went to the Research Laboratory
of the Royal Cancer Hospital in 1936, and he directed a superb team of people who were
able to synthesize a whole range of different chemical substances. In fact, one of his earliest
drugs was urethane (ethyl carbamate) and that was the first drug that was used in the
treatment of cancer.36 He went up to Manchester to liaise with Edith Paterson, who was the
wife of Ralston Paterson, the Director of Radiotherapy at the Christie Hospital. I think that
Edith must have contacted John Wilkinson, who was Head of the Department of
Haematology at the Manchester Royal Infirmary at that time, because they both got
together in the treatment of CML. Although their initial experiments with urethane weren’t
great, they did in fact show a reduction in white cell counts in patients with CML. In 1946
they published a paper together, showing the responses in CML.37
The real advance came with the introduction of busulphan38 by that team and it was David
Galton, who actually introduced that compound for the treatment of CML, where it has
Leukaemia
14
39 Hodes M E, Rohn R J, Bond W H. (1960) Vincaleukoblastine. I. Preliminary clinical studies. Cancer Research
20: 1041–1049. See also Noble R L. (1990) The discovery of the vinca alkaloids: chemotherapeutic agents
against cancer. Biochemistry and Cell Biology 68: 1344–1351.
40 See Revera G K. (1993) Treatment of acute lymphoblastic leukemia: 30 years’ experience at St Jude  Children’s
Research Hospital. New England Journal of Medicine 329: 1289–1295.
41 See, for example, George P, Hernandez K, Hustu O, Borella L, Holton C, Pinkel D. (1968) A study of ‘total
therapy’ of acute lymphocytic leukemia in children. Journal of Pediatrics 72: 399–408. Pinkel D. (1972) Total
therapy of acute lymphocytic leukemia. Journal of the American Medical Association 222: 1170. Pinkel D,
Simone J, Hustu H O, Aut R J A. (1972) Nine years’ experience with ‘Total Therapy’ of childhood acute
lymphocytic leukemia. Pediatrics 50: 246–251. Professor David Galton wrote: ‘Donald Pinkel was a disciple of
Sidney Farber, and it was Farber who emphasized “Total Care” as the ideal clinical approach to the treatment of
acute leukaemia.’ Note on draft transcript, 29 November 2002.
stood the test of time. It was the essential main base of treatment for several decades, so we
have a great deal to thank David Galton for. 
The 1950s showed the development of a large number of single agents in the treatment of
leukaemia. We have mentioned that chlorambucil was introduced at the Chester Beatty to
treat chronic lymphocytic leukaemia and, in fact, it remains one of the mainstays of
treatment, even today. Melphalan was introduced, as John has mentioned, but of course
that was for the treatment of myeloma by and large rather than leukaemia, although it has
been used for leukaemia.
In the 1950s, the single agents that we used were busulphan, chlorambucil and 6-MP. In
addition there were other drugs that were in the offing, such as the vinca alkaloids that are
derived from Vinca rosea, the Madagascar periwincle which is also called Catharanthus
roseus. The vinca alkaloids were developed in the late 1950s,39 so it was a great time for the
synthetic chemists who prepared these derivatives from natural products. 
I personally know a little bit more about the history in the early 1960s, because I was a
houseman and a Wellcome Clinical Research Fellow for three years in the mid 1960s, and
was supervised by Gordon Hamilton Fairley. I eventually became Senior Registrar to Sir
Ronald Bodley Scott at Bart’s in 1968, so I saw the development from the viewpoint of a
houseman and senior registrar at that time. The major development in the treatment of
acute lymphoblastic leukaemia (ALL) in my mind came from the USA. It came from St
Jude Children’s Research Hospital in Memphis,40 with Don Pinkel introducing what he
called ‘Total Therapy’.41 He had Total 1, Total 2, Total 3, and so on – a series of superb
clinical studies. Most of them weren’t randomized studies; they were just single studies of
50 patients here, 100 patients there. They would be considered to be old-fashioned now,
but when he conducted those very elegant experiments during the 1960s, the principles
that were applied resulted in the regular cure of more than 50 per cent of children with
ALL. These principles were induction therapy using weekly vincristine and prednisone, a
period of ‘maintenance’ chemotherapy using 6-MP and methotrexate, and then
radiotherapy to the central nervous system to prevent meningeal relapse. With those
treatments a tremendous increase in the survival rate of patients with ALL resulted. In fact,
the treatment of adult ALL wasn’t far behind, although it took longer to develop. 
The advances in the treatment of AML were slower and it was much more difficult. I attended
the ASCO [American Society of Clinical Oncology] meetings in the mid-1960s, which were
attended then, as I remember, by one or two hundred people. Today, the ASCO meetings are
attended by many thousands of people, but in those years they were talking about single-agent
therapies for AML. Cytosine arabinoside was being used with a 16 per cent complete remission
rate.42 Daunomycin was being used, or daunorubicin, as it was called by the French. The
successful introduction of an anthracycline in the study of acute leukaemia came from Jean
Bernard’s group in Paris; that was a superb team – it was well organized and they conducted
some very good studies. They produced, using daunorubicin, almost a 50 per cent complete
remission rate in patients with AML during the 1960s.43 The unfortunate thing about it was
that it was very cardiotoxic, and when I joined Bart’s as a Senior Registrar in 1968, there were
patients on the ward dying with heart failure. Jim Malpas was the previous Senior Registrar,
and he had treated patients with AML using daunorubicin on a five-day schedule derived from
Jean Bernard’s work; there were several patients actually dying of cardiotoxicity on the ward at
that time when I took over. He told me about the scheduling and said, ‘Look, don’t try to repeat
the Jean Bernard stuff, because it’s very cardiotoxic – watch it’. 
In 1968, Sir Ronald Bodley Scott, Gordon Hamilton Fairley and myself organized a
combined chemotherapy with cytosine arabinoside and daunorubicin given together. At the
time it was a pretty hairy prospect I can tell you for the decision to do it was considered only
briefly and over coffee. I had suggested to Sir Ronald, who was running the ward rounds, that
perhaps we could use a drug combination – because combinations were useful for Hodgkin’s
disease and had been used for ALL – and maybe we should use a combination for AML.44 He
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said, ‘Go carefully because the patients are often severely pancytopenic already’. However, we
did carry out myeloablative types of therapy with that combination and reported a complete
remission rate of 62 per cent.45 At the time, Barney Clarkson and Tim Gee in New York in the
Memorial Hospital were using thioguanine and cytosine arabinoside to try to get complete
remissions, and they achieved a complete response rate of about 40 per cent in 1969.46 So when
the 1970s broke it was decided, by a number of groups within the UK, that we should add
thioguanine to cytosine arabinoside and daunorubicin. That combination proved to be quite
effective in the 1970s and was, in fact, the subject of a number of MRC trials at that time.47
Another development in the 1960s that we need to remember was that an international
definition of complete remission in AML was brought into play and it was generally accepted
that AML could be distinguished from ALL. It seems strange at this time that we should think
there was a problem with this distinction, but there was in the 1960s. For example, 
J Freireich48 was treating all his patients with acute leukaemia in Houston with the same
chemotherapy and wasn’t bothering to distinguish the type of leukaemia. The recognition that
AML could be split into different groups was very important. Jean Bernard showed that acute
promyelocytic leukaemia could have very long-term remissions with chemotherapy and he
found that this type of acute leukaemia was very responsive, although there were difficulties
in the induction phase, and this kind of leukaemia came to have long-term survival.49
Towards the end of the 1960s Georges Mathé introduced immunotherapy for the treatment
of childhood ALL in complete remission,50 and although some patients had apparently done
quite well, later years showed that it was of little value. Subsequently, bacterial products such
as BCG or Bordetella pertussis and irradiated leukaemia cells were used in the treatment of
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adult AML in remission.51 Ray Powles, who is in the audience, developed this. This was a
project that was organized by Peter Alexander and Gordon Hamilton Fairley, who made a very
good duo in the late 1960s. Peter Alexander led the way in tumour immunotherapy and the
understanding of it in the experimental sense.52 In the late 1960s, he linked up with Gordon
Hamilton Fairley, who gave a great thrust to the development of what was to become medical
oncology. Unfortunately, Gordon Hamilton Fairley died as a result of an IRA bomb in 1975,
and this took away someone who was the major influence in the development of medical
oncology in the UK at that time. This was a real disaster for the speciality of medical oncology.
In the 1970s we came to the era of intensive chemotherapy. Some intensification had been
provided and the treatment of AML was resulting in longer-term survival – 20 per cent
were beginning to live three to five years – by the end of the 1970s, through the
introduction of more intensive procedures. 
But it wasn’t until the introduction of bone marrow transplantation (BMT) that
myeloablative chemotherapy became feasible. Razjock in 1939 was the first to give marrow to
a leukaemic patient; he gave it directly into the marrow cavity.53 It wasn’t until 1957 that
Donnall Thomas and his colleagues in Seattle showed that a large volume of marrow could be
infused safely, resulting in transient engraftment.54 In 1963, Georges Mathé – a horrendously
hard worker, who developed many things in the 1960s – published the first report of the long-
term survival of a patient with leukaemia following transplantation. He was also the first to
describe graft-versus-host disease (GVHD).55 It was only in the 1970s that BMT became of
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practical value; it was the Seattle group that produced extensive experience on HLA-matched
allogeneic transplantation and BMT  with minor mismatches, and showed that a graft-versus-
leukaemia reaction had a beneficial effect.56
Three principles were proposed in the late 1970s from quite a large number of cases studied –
myeloblative therapy could minimize the leukaemic cell population; HLA-matched, or minor
allogeneic mismatched BMT, could allow haematopoietic recovery, and the third, exploitation
of the role of the graft-versus-leukaemia effect. Subsequently this approach has been widely used
throughout the world and has been shown to improve survival in a number of haematological
malignancies. Our chairman, Professor John Goldman, has been responsible for some of these
rather important advances, particularly in the management of CML. 
In the 1980s we come to the age of applied molecular biology and recombinant technology. The
first recombinant molecule that was introduced into the clinic was recombinant alpha-interferon
– in 1981, I think.57 This was subsequently introduced into the treatment of CML with some
effect, but the more important agents that were introduced during the mid-1980s were the
recombinant haemopoietic growth factors. G-CSF [granulocyte colony-stimulating factor] had
been discovered mainly following experimental work by Don Metcalf ’s group in Melbourne,
Australia. Recombinant DNA technology allowed their pure production and, lo and behold, G-
CSF was made available for patients in the mid-1980s. I wrote a protocol at that time that was
sent into the Leukaemia Research Fund (LRF) for funding a student of David Weatherall’s,
Miguel Bronchud, who had been working in Oxford. The grant request was to conduct a phase
I–II study with stem cell factor; however, stem cell factor didn’t come along until much later. It
was almost ten years before stem cell factor could be introduced in the clinic. It was thought that
GM-CSF [granulocyte-macrophage colony-stimulating factor] was ready to go and so we wrote
the grant request for GM-CSF instead. We got the clinical research fellowship from the LRF to
conduct that study. Unfortunately, GM-CSF was not available either, but G-CSF had been
produced by a new drug company called AMGEN, in the USA. We finally did a phase I–II study
of G-CSF using intensive chemotherapy in lung cancer patients, and showed that there was an
enhancement of neutrophil recovery following chemotherapy and a reduction in the
incidence of infection. The paper was published in 1987 by members of the Department of
Medical Oncology and Experimental Haematology in the Paterson Institute in Manchester.58
Another observation in the 1980s was by Huang in China, who observed that there was a
remission using all-trans-retinoic acid in the treatment of acute promyelocytic leukaemia
(APML).59 This was interesting, because molecular technology had shown that APML was
a result of a translocation involving the retinoic acid receptor gene on chromosome 17 and
the PML gene on chromosome 15. An explanation of the molecular mechanism of action
could therefore be suggested.
The use of haemopoietic growth factors set the stage for the 1990s, when it was found that
myeloablative chemotherapy could be carried out more easily and safely with haemopoietic
rescue using peripheral blood stem cells collected following G-CSF treatment. The original
studies were done by Sheridan in Melbourne, who used peripheral blood stem cells in
conjunction with bone marrow, and showed that the recovery in granulocytes, neutrophils
and in platelets was much faster than bone marrow alone.60 Subsequently quite a large
number of people, including ourselves in Manchester, did some work showing that you
could use peripheral blood stem cells alone for haematopoietic rescue.61 The technique has
become widely used and is now used for lymphoblastic disease, ALL, AML and CML. The
role of myeloablative procedures continues to be addressed in the new millennium. 
Goldman: Thank you very much, Derek. That was a very beautiful overview of quite a
number of things. Can I make one comment and then I am going to ask David to make a
comment? After that I want to introduce a slightly new topic. 
My comment is simply an anecdote that supports something you said at the beginning of
your talk. I had a patient with CML who was doing rather badly, and round about 1990
she decided to go to India for therapy. She had heard of a practitioner called Dr Vadya
Prakash, operating in Delhi and in Deradan. She spent about six weeks there and she came
back and said it wasn’t very effective. But the LRF led by Gordon Piller suggested that it
would be worth looking at the particular compound that Prakash was using to treat
predominantly CML. In conjunction with two other haematologists, I went to Delhi to
look at this compound. There was no doubt that the compound that Prakash was making
in his back garden and in his kitchen sink was controlling the leucocyte count. The
leucocyte count of patients with chronic leukaemia was coming down in some cases to
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normal. To the annoyance of the All-India Institute of Medical Sciences and Lady Tata
Memorial Hospital, he was building up a considerable practice in his own private office in
Delhi. He didn’t know what was in the compound, or he told us it was a mixture of things
he made in his back garden. I guess many people will have got an idea where we are heading;
we brought the compound back to London for analysis and, of course, it contained between
15 and 25 per cent arsenic. We wrote about this, as it was a partly modified ayurvedic
medicine.62 This was before the time that arsenic underwent the renaissance to which you
referred a few moments ago, Derek, but I suppose the moral of the story is, (a) to keep an
open mind, and (b) note that some of the old remedies may actually recur on one. David,
you were going to say something?
Galton: I wanted to comment on three of the things that we have heard this afternoon. The
first one is again arsenic. You would hardly believe it, but arsenic was still being used in
Switzerland in the 1950s. I had a patient referred by a very, very distinguished Swiss
haematologist, Karl Rohr, whose name many of you will know, because he had heard of
busulphan. This patient had been treated with arsenic and I discovered that it was quite
commonly used in Switzerland at that time. 
The second point that I wanted to make was to go back to Alex Haddow and urethane,
because Haddow had a remarkable brain – he kept his eyes open and picked on things of
interest from every sphere. He met up with a plant pathologist whose name was Sexton,
who had found that if he germinated cereals and onions, the mitosis in the root tips could
be arrested by urethane, or one of its analogues. Haddow, of course, immediately got onto
it and found that it was a very good inhibitor of some of his experimental tumours,63 and
that’s how it worked its way into clinical practice. He had collaborated with Ralston
Paterson [of the Christie Hospital in Manchester], who was a fellow Scot, and that’s how
Paterson got onto it. 
Now an interesting little side story about this is that at the time that Edith Paterson was
studying urethane, so was a young clinician at the Royal Cancer Hospital. Because of Edith’s
radiotherapy training, she had regular blood counts done on her patients treated with
urethane and it was she who noticed the fall in the blood count in patients without
leukaemia but with malignant diseases.64 Haddow was a bit cross about this because it had
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been totally missed by the young lady who was studying this compound at the Royal
Cancer Hospital. Anyhow, an amusing thing is that one of the people who received
urethane to test, from Alex Haddow, was Harold Himsworth, who was then Professor of
Medicine at University College Hospital. At UCH this drug was known as the ‘Manchester
drug’ because the finding of a depressed leucocyte count came from Manchester.65
Another interesting point about urethane is that it made patients dreadfully sick and it was
very difficult to get them to tolerate it. One of the people who had received urethane in the
USA was Wayne Rundles at Duke University in North Carolina. He was a physician, a
haematologist, and he could do what he liked in treating patients. This wouldn’t have been
possible in this country with say myelomatosis, because myeloma was treated by
radiotherapy. In the 1950s radiotherapists were, let’s put it in a general way, the custodians,
if you like, of the knowledge, the science, of malignant disease. They were the ones who
kept registers, they were the ones who knew how long people survived, and they knew the
natural history of the disease better than anyone else. So they had, rightly I think, a rather
lordly attitude to radiotherapy in relation to the new-fangled drugs. They were highly
suspicious of them and I think they were probably correct. But with myeloma they went
too far, because they used to treat this disease, which mainly produced terrible bone pains
in different parts of the body, by irradiating one painful site after another. They went on
doing this until the patients were in severe renal failure on the one hand, or bone marrow
failure on the other. At that stage they were handed over to people who were trying
chemotherapy drugs and, of course, all that the drugs did was kill the patients, because they
were now in total renal failure, and/or pancytopenia. Wayne Rundles wasn’t under any such
constraints and he treated myeloma patients with urethane with great success.66
Furthermore, he developed a way of giving it by suppository and this reduced a good deal
of the nausea and vomiting. I must say that this raises a general problem about the
introduction of these agents in the UK, because I think it wasn’t only the radiotherapists
who were highly sceptical. Most physicians were very reluctant to handle these drugs, and
it was a hard core of wonderful people who saw their potential and their future, and it was
they who gave us a lot of support.
Derek told us about Ronald Bodley Scott; he was at the forefront of those who supported
the new studies. At Hammersmith there was John McMichael and Russell Fraser, who gave
the opportunity for using these drugs at a time when most physicians were not at all
friendly to them; there was also Percy Thompson Hancock and John Harman, who gave
encouragement at the Royal Marsden Hospital. 
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Incidentally, somebody mentioned aminopterin. Here’s another little story. Sidney Farber
had just done the first studies on childhood leukaemia with aminopterin.67 I think it was
February 1948 when a well-known poet, who was also an amateur mountaineer and a
school teacher, had been on holiday in Switzerland mountaineering, and to his horror found
that he was getting breathless when he got beyond a certain height. He was worried about
this and on his return his wife, who was a Scottish girl and also a poet, persuaded him to
seek medical advice. He was diagnosed as having acute leukaemia and was referred to John
McMichael at Hammersmith. But his wife was a Scot who knew Alex Haddow, and she
asked Alex if there was anything that could be done to treat this awful disease, because she
had heard that it was incurable. Haddow said there was probably nothing, but a colleague of
his, Professor Eric Boyland, had just received a supply of a new drug which had come from
America and that was doing unexpectedly good things in the treatment of childhood
leukaemia; he asked if she would be prepared to let her husband receive this drug. Of course
she was only too delighted and I took over Eric Boyland’s aminopterin. This would be
impossible today – you would have to fill in all kinds of forms and it just couldn’t be done –
but I took this stuff over, and John Dacie and I studied the blood of this patient. He had a
horrible form of leukaemia that would now be called M5 – acute monocytic leukaemia. John
McMichael’s team treated this patient with the drug. He went into a complete remission,
something amazing, because nowadays none of the folate antagonists is used in the treatment
of this disease. He had three months of good life and then he relapsed with multiple skin
nodules, came back to Hammersmith, had more aminopterin, but it did no good and he
died. His wife went to see Alex Haddow afterwards and he was deeply apologetic for having
inflicted what proved to be a useless treatment on her husband; he felt that it shouldn’t have
been done, but the wife said, ‘On the contrary, these three months were almost the best three
months of our lives. Every day of good health was appreciated and it was wonderful, thank
you very much.’ That was the second thing I wanted to touch on. 
The third was that Derek spoke about the advent of BMT. I think one of the first bone
marrow transplants ever given in the UK was – don’t laugh – by Humphrey Kay. I had a
patient who had CML, who unfortunately had received busulphan for two weeks longer
than she should have. I was very foolish; she was going on holiday and I gave her a supply
two weeks beyond her next appointment. She didn’t keep the appointment; she went on
taking the drug, became pancytopenic, and arrived back in this terrible state. Humphrey
said, ‘Why don’t we try to get some bone marrow from a donor that could be easily obtained
by asking Mr Barrett (who was one of the surgeons at the Brompton Hospital next door),
if he would agree to cut out a few ribs next time he was doing a thoracotomy – and could
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we please have the marrow? That’s exactly what he did. Humphrey filtered it off to get rid
of the fat, and of course in those days (1953), nobody knew anything about
histocompatability groups at all. Anyway she had the marrow but I am afraid she died. 
Goldman: Can I just ask you to comment briefly on one of your earlier points? You said
that radiotherapists and some other physicians were not very well disposed to the use of
chemotherapeutic agents to treat malignant disease. What was the response of the
radiotherapy community to your publication on busulphan versus radiotherapy in CML? 68
Galton: By that time they had become extremely cooperative. The point is that they raised
no objections whatever – in fact they were fully supportive when the Medical Research
Council Working Party wanted to put on this trial of radiotherapy versus busulphan,69 and
we had nothing but cooperation from them.
Goldman: That was not because they expected radiotherapy to be better, but because they
were genuinely interested.
Galton: They wanted to find out which was better. The other thing was after a few years
of, I suppose, hostility, radiotherapists welcomed the advent of chemotherapy. In fact, at the
Royal Marsden Hospital, David Smithers, who was Head of Radiotherapy, arranged for a
joint consultation clinic between Elspeth Ledlie, who was one of his radiotherapists, and
myself to see patients with malignant lymphoma once a week. Constance Wood, at
Hammersmith Hospital, slightly reluctantly I think, arranged for me to have a joint clinic
once a week with Leon Szur, one of her radiotherapists who dealt mainly with lymphoid
neoplasms and so on. These were very valuable.
Dr Eve Wiltshaw: I would like to confirm what David [Galton] and others have said about
the Institute of Cancer Research when Haddow led it. I think it was the golden age for the
Institute of Cancer Research70 and I was very glad to be part of it. I came to the Institute
from Boston at a time when [Maxwell] Wintrobe was around. The Boston haematologist,
William Dameshek, was showing off every week with his foreign patients and the children’s
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hospital [under Sidney Farber] was starting its treatments for acute leukaemia and later for
other tumours. I had gone to Boston because I knew that nobody in London would take
me on, having come from a university called the University of Wales. I was quite right in
that and after two years I came to London and saw Haddow, because I had a letter of
introduction from my own haematologist. Haddow and David told me, ‘Go and see John
Dacie about your future’. So, with two years of clinical haematology behind me, treating
leukaemia and lymphomas, both laboratory-wise and in the clinic, Dacie said to me, ‘But
Eve, you are not considered a proper doctor. In the UK you are not a proper physician
because you have been in the lab, and you are not a haematologist because you have been
treating patients. Go back to America.’ I didn’t want to go back to America, because I didn’t
like the way they lived. The fact was that this country then had haematologists who worked
in laboratories and doctors who didn’t know anything about haematology, treating patients
with haematological disorders and nobody was prepared to make the obvious change. 
You have all been talking about various innovations, new drugs, new methods, and new
ideas, but there wasn’t, apart from Haddow and his colleagues, a single UK advance. I am
not taking this up to the present, but I am talking about the 1950s and 1960s. We had got
some drugs from the Institute of Cancer Research, and we had got a lot of different ideas,
which mainly came from America, based on the fact that they were willing to take risks.
There were no risk takers here. There was no medical oncology – there wasn’t much medical
oncology in the USA, but there was none here. I remember trying to get jobs. The only
doctor who was interested in me having a job outside the Marsden and the Institute was
David Weatherall; otherwise people said, ‘What do you mean? There is no subject. Why
don’t you do radiotherapy?’ [From the floor: What year was that?] When I started looking
for a job? Oh, the mid-1960s, and even now, we are short of medical oncologists.
Goldman: What about David Galton, he didn’t get appointed? I don’t think he was a
consultant for many years. 
Wiltshaw: David is too nice to everybody, even now. They kept him out of a position of
responsibility and the ability to do anything for a long time, and it was because they used
the clash between the Institute and the Hospital to do that. I suspect that’s one of the
reasons why David left in 1969 to go to the Hammersmith Hospital full time. 
Professor Daniel Catovsky: I just want to put the record straight, at least on the late 1960s
and early 1970s, about Sir John Dacie and the Hammersmith and David Galton, because
they started the first leukaemia unit in the UK. Maybe I don’t know where we learnt great
advances, but Sir John Dacie was instrumental later on, maybe not in the 1950s, in
changing the philosophy of haematology through bridging the gulf between the laboratory
and clinical branches. He had very good clinicians in his group, like Michael Brain and Ted
Gordon Smith. 
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When I was about to go back to Argentina in 1970, David encouraged me to stay in the UK
and work with him. Then John Goldman and Alexander Spiers came to join us in forming
the first Leukaemia Unit. Although the MRC provided financial backing and David Galton
directed the Unit, it was Sir John who was responsible for its formation, so it is he who
changed the early philosophy and eventually the direction of haematology in the UK.
Sir Christopher Booth: I just wanted to support that view. I became Professor of Medicine
in succession to John McMichael at the Hammersmith in 1966. The chairman of the board
at that time who promoted my appointment to that post was John Dacie. I had worked in
his department as a haematologist before I became a gastroenterologist and he was
particularly involved in this question over the clinic and the laboratory at that time. After I
was appointed, my first senior registrar was Michael Brain, who had a joint appointment in
my department in medicine and with John Dacie in haematology. Within two years of my
appointment John Dacie was making rounds in the American way of seeing patients. I do
know that he was deeply committed to clinical haematology, which led to his promotion of
the Leukaemia Unit at the Hammersmith, which has been so successful.
Powles: Following on from Derek’s [Crowther] nice summary about the Bart’s side of things
reminds me of exactly what it was like for the patients being treated in the early 1960s. I
was a student on Bodley Scott’s firm in 1962 and a houseman on the same unit for a year
in 1965. There were up to 40 in-patients at a time with leukaemia and many others
scattered in other wards throughout the hospital. Most had acute leukaemia and the median
survival from diagnosis was about 12 weeks. Probably 1000 went through Bart’s in this
period and I don’t think there was a single long-term survivor.
As a houseman, the dominant duty was putting up intravenous drips in the morning using
Guest cannulae and taking them down again in the evenings. We might be putting up 30
or 40 drips per day and preserving the veins was all that was keeping these patients alive.71
Young patients when first admitted would start in a bed at the far end of the ward and
would work their way up to the two single rooms that were at the entrance to each ward,
where two or three of them would die every day – of course, some of the patients didn’t even
know they had leukaemia in those days, which was the standard practice of those days. 
Now, just following on from Derek about the drugs – vinblastine was interesting. We gave
vinblastine daily and this often led to devastating paralytic colitis requiring the raising of a
caecostomy – it was only the colon that was paralysed, not the small bowel. We learnt quite
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quickly to give the drug weekly. At that time Hamilton Fairley and John Matthias were the
senior registrars followed by Jim Malpas and subsequently Derek Crowther. Daunorubicin
was also introduced at this time and given in very high doses; consequently I saw more
cardiomyopathy in this period than in my entire subsequent career. Leukaemia drugs were
not yet being used in combination and platelet transfusions were only just becoming
available following the extraordinary vision of Isaac Djerassi in Philadelphia.72
In 1968 I joined Peter Alexander and Hamilton Fairley at the Royal Marsden Hospital in
Sutton, Surrey, where they set up a Tumour Immunology Research Programme looking at
the possibility of undertaking immunotherapy as treatment for leukaemia following the
pioneering work of Georges Mathé at Villejuif in Paris.73 I spent four months with Georges
learning all about BCG. In Sutton, Humphrey Kay already had a most imaginative 
state-of-the-art leukaemia unit treating children in plastic bubbles that could be made germ
free. The ‘Concord trial’ started at this time under the auspices of the MRC74 to see if BCG
versus nothing could be tested for the maintenance of remission of children with leukaemia.
These children did not have any CNS prophylaxis and I think the median survival was 32
weeks. It was at this time that it was shown at St Jude’s Hospital in Memphis, Tennessee that
CNS prophylaxis actually produced cures.75
Goldman: I want to move on to morphology in one moment, but before that I just want
to take up your last point, Ray, which is the word cure. I would like somebody, maybe
Humphrey, to comment on the transition in concept from the idea that children could
never be cured of their leukaemia to the idea that cure could become a reality. I don’t want
to trespass on what John Lilleyman might be saying in a few moments. Humphrey, do you
want to comment on the notion of cure?
Professor Humphrey Kay: The first cases we were interested in were Joe Burchenal’s cases, weren’t
they? He had two or three who appeared to be totally cured and all the haematologists thought
he had got the diagnosis wrong – they must have been cases of infectious mononucleosis.
Goldman: If the patient survived then the diagnosis had been wrong?
Kay: Yes. But gradually we had to revise that.
Galton: One point, when Derek was talking, he was speaking about technical advances and
how they influenced the development of treatments.76 This is supposed to be a historical
meeting. Ray spoke about platelet transfusion. I think very few people below a certain age
can remember our working conditions in the early 1950s. For example, nowadays people
use butterfly cannulas for intravenous transfusions and they can do all kinds of things with
them.77 In our day we had dreadful glass syringes; they had a central nozzle and there was
no way you could get into a small vein – we always had to use the cubital fossa veins. If we
wanted to put up a drip, for example, we had to rummage about in a great cardboard box
where there were lots of rubber tubings of different sizes, and we had to fit these up and
stick them into a glass rod that fitted into a hole in a cork in a bottle – we didn’t have any
plastic transfusion equipment.78 All this took a great deal of time. There were no platelet
transfusions. I felt that we could stop our acute leukaemia patients from dying a miserable
haemorrhagic death if we could get very fresh blood into them. Where were we going to get
fresh blood? Very fresh. We had a system whereby we would invite two or three donors –
do you remember that, Eve? Then one of us would bleed the first donor; the other one
would put up a drip into the patient, and the idea was to get this blood in while it was still
warm. Of course we had the cross-matching business, and it took a very long time to get
three units of blood taken in such a way that they were really fresh and went in ‘hot’. We
did find that the patients stopped bleeding for several days, [to Eve Wiltshaw] wasn’t it? But
this was a terrible palaver and I think at about the same time Gordon Wetherley-Mein wrote
about it.79 I think anyone from St Thomas’s can tell me when that happened. He was trying
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to get very fresh blood to get platelets in quickly. So we forget nowadays what a palaver these
things were and the sheer time wasted in doing these things was quite extraordinary.
Dr Peter Hunter: Just a very quick question. What is the date of the first very fresh blood
platelet transfusion?
Powles: Platelet transfusions were about 1968–69. That’s when they were certainly being
effectively used. I don’t know about fresh blood.80
Hayhoe: Regarding fresh blood, I think Whitby was certainly using it at the Middlesex
before the war and you remember he very largely organized the blood transfusion services
during the war – during the Second World War.81
Goldman: No, I think it goes back further than that.
Crowther: I think it was carried out on a man who lost his leg in the First World War. It
was tried several times in the First World War and sometimes it was useful and sometimes
it wasn’t. They didn’t understand about compatibility. I heard that in the trenches direct
blood transfusions were given but several soldiers died from incompatibility. I think they
used animal blood in the nineteenth century.82
Goldman: Animal blood was certainly used experimentally. It would be difficult to get it
through your research ethics committee today, though. What about prophylactic antibiotics? 
Powles: In 1965 we were using oral chloramphenicol and erythromycin as the main
treatment of infection; they were given in combination and this was considered extremely
innovative and against the standard accepted wisdom for using antibiotics.83
Piller: Exchange blood transfusion was started first at Bart’s Hospital in the middle of the
nineteenth century and also at Great Ormond Street Hospital for Sick Children.84 In one
case the blood that was administered was from an animal and in the other from a human,
both without success. As far as I know, the first complete blood exsanguination transfusion,
born of desperation, was given in a case of leukaemia by Jean Bernard and Marcel Bessis in
1947.85 The result was a temporary remission of a few months – when a remission in cases
of acute leukaemia was almost unknown at that time. 
Goldman: I think the issue of ‘first’ is often very difficult to work out because it depends
on how you define the blood transfusion or indeed the bone marrow transplant as we
mentioned already. I would like to raise just one question. Does anybody here have some
experience of blood transfusion inducing remission of acute leukaemia?
Hayhoe: I had extensive experience of this in the early 1950s, when I went as an Elmore
research student to join Lionel Whitby’s unit in Cambridge. There initially the only form
of treatment was blood transfusion and prayer for acute leukaemias; we didn’t yet have 
6-MP. The folic acid antagonists were just beginning to be used, and of course prednisolone,
cortisone and adrenocorticotropic hormone (ACTH) were also just beginning to appear.
Most of our patients were given blood transfusions, preferably very fresh, and a proportion
of them undoubtedly went into full, though relatively short-term, remission. If you look at
the British Journal of Haematology, volume one, page one, you will find a paper by Lionel
Whitby and myself, in 1955, describing our experience, which included maybe a dozen or
20 patients.86 It was also actively practised in Paris, and Bessis particularly used
exsanguination transfusions to produce remissions in ALL in children, and produced a high
proportion of them. Whether this was due to a steroid effect or what really mediated it, I
am not sure.
Galton: Just a very quick point. I very well remember receiving that very first paper from
Frank and Lionel Whitby. John Dacie gave it to me. It was the first paper for the new British
Journal of Haematology that I edited in 1955. Lovely.
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Goldman: I think we should change topic now, quite radically, and talk about morphology.
Maybe Frank, you could start briefly and we will go on to Danny, and David, in that order.
Hayhoe: I think that to approach the subject of morphology, I have got to divide it into
about four main sections, with a couple of subsidiary sections. I was asked to do it in five
minutes, and I shall try to do something of that sort. 
The first is the use of panoptic staining, introduced by Paul Ehrlich in 1877 or thereabouts
but still substantially used today.87 The Romanowsky dyes, basically eosin and methylene
blue mixtures in methanol, which were long used in this country in the form of either
May–Grünwald–Giemsa or Leishmann stains, in the USA as Wright stain, and more
recently in this country as Heyl stain or some other purified form of azure B and eosin Y.88
These panoptic stains produce a very effective delineation of the morphological structure of
leukaemic cells. The problem was that although haematologists recognized the differences
between almost as many classes as we recognize today – if you look at Forkner’s 1938
Textbook on Leukemia and Allied Disorders,89 you will find that he subdivides the
leukaemias into virtually as many categories as we include today, various myeloid groups,
monocytic, lymphoblastic, those with erythroid components, those with megakaryocytic or
megakaryoblastic components, eosinophilic predominance and so forth – it was all there at
that time. There was a powerful difficulty about the use of these stains. Although every
skilled haematologist reckoned that he could subdivide the leukaemias accurately, in point
of fact there was very wide disagreement. If you look at the recorded figures from different
areas of the USA, as to the proportion of lymphoid to myeloid leukaemias for example, they
vary enormously, despite the fact that the most disparate figures often came from
neighbouring regions in the USA. When in the early 1950s, the new forms of treatment
which we have been discussing earlier, became available for the leukaemias, the Medical
Research Council set up Working Parties on the treatment and, as a preliminary, on the
typing of leukaemia. With Leslie Witts as chairman, a small working group was designed to
see to what extent we could agree on our classifications. I was the secretary of this group and
we arranged for a number of centres to send slides from every new case of leukaemia to me
in Cambridge. The participants in this study included Leslie Witts himself and Sheila
Callender from Oxford, John Dacie from the Hammersmith, David Galton then at the
Marsden, Gordon Wetherly-Mein from St Thomas’s, Ronald Bodley Scott from Bart’s, Roger
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Hardisty from Great Ormond Street and Bill Davidson from King’s. In addition, we brought
in Eric Easson, James Fountain, C A Holman, Eddie Blackburn from Sheffield and R B
Thompson from Newcastle. That made 13 people altogether, to whom we circulated the
slides with their identity and origin masked. We circulated 100 slides. About 50 of them were
of chronic leukaemias, chronic myeloid or chronic lymphocytic, and the 13 people by and
large agreed on these. The other half of the cases were acute leukaemias. We had not specified
the labels that should be put on the acute leukaemias, and left it to each individual to put
their own label on it. Of the acute leukaemias sent round to these 13 observers, not one
single case had an agreed diagnosis; some cases had eight or nine different diagnoses from the
same slide. So at this stage, I played an unpleasant trick, and took six of the cases that had
shown the most disparate diagnoses, relabelled them and circulated them again as fresh
slides. We didn’t get any better agreement the second time round, but many of the observers
gave a different diagnosis on their second reading from what they had given at the first. 
It was as a result of that study, and partly because in 1951 I had presented an MD dissertation
at Cambridge on the use of cytochemistry in haematology,90 that I thought it was a good idea
to apply cytochemical techniques more widely. I am not going to discuss this second major
morphological contribution in detail now, but simply to say that as a result of the study of
another 140 cases, using particularly the Sudan black and PAS [periodic acid–Schiff ]
reactions, as well as peroxidase, we were able to establish a reasonably satisfactory pattern of
diagnosis that became generally used subsequently in later MRC trials.91
I have to move on quickly from the use of panoptic and cytochemical staining, which still
continues today, to the next supplement following cytochemistry, which was cytogenetics.
This, of course, is another component of morphology. Remember that when we were
starting this work, the human chromosome number was not known – it was generally
thought to be 48.92 In fact Tjio and Levan showed the number to be 46 in 1956.93
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The first paper that I remember which showed that the chromosome pattern might be
abnormal in acute leukaemias came from Ford, Jacobs and Lajtha in 1958.94 From that time
everybody got pitched into a study of chromosomes in acute leukaemias. I did, among
others. Dennis Quaglino, who was then working with me, and I went down to St George’s
[London], where Stafford and Kemp had started to get satisfactory metaphase spreads, to
learn their technique.95 We started using it in Cambridge and by 1964 we were able to
report on something like 20 or 30 cases and find another 200 or 300 in the literature.96 But
at that stage, all that the early morphological chromosome studies were doing was spotting
numerical and structural defects among which the Ph chromosome of CML was the most
important.97 There weren’t the techniques available yet to distinguish the different
chromosomes, other than very crudely by their size, and you couldn’t separate the 6–12
group anyway. In 1970 Caspersson introduced quinacrine banding, Q banding and Giemsa
banding quickly followed.98 With the use of high-resolution Giemsa-banded chromosomes,
you could identify individual chromosomes and start to find specific translocations. It was
with Giemsa banding that people both in Scandinavia, this country and also in the USA,
particularly Janet Rowley’s unit, began to find and report the now well-known
translocations that occur in acute leukaemia.99 Following that, with the subsequent
development of molecular biological studies, which followed 10 or 15 years later, it became
possible to produce highly specific probes for individual chromosomes. Using techniques
such as fluorescence in situ hybridization (FISH), localized translocations and defects of one
kind or another were much more widely explored and defined. I see that nowadays multiple
staining methods are available, with multiple FISH techniques that enable you to paint
every individual chromosome a different colour and spot whether bits of it have gone here
or there. This is the expanding contribution of cytogenetics to morphology. 
Finally, the contribution of immunology to morphology followed when cytochemical
immunological techniques became available to demonstrate the presence of particular
surface antigens. The beginning of this was Mel Greaves’s discovery of an antibody reacting
with the common ALL surface antigen,100 but of course in 1975 when César Milstein and
Georges Köhler published their techniques for producing specific monoclonal antibodies,
we then got a fantastic development.101 I don’t know how many monoclonals there are on
the list at the moment, it must be at least 150 or 200 and many of these, perhaps 30 or so,
are of importance to haematologists. With their use, demonstrable morphologically by
techniques like the avidin–biotin peroxidase methods and the APAAP (alkaline phosphatase
anti-alkaline phosphatase) technique, you can demonstrate what particular surface antigens
there are in leukaemia cells.102 Those are the main techniques in leukaemia morphology:
panoptic staining, cytochemistry, cytogenetics and immunocytochemistry. 
I'd like just briefly to mention and then to dismiss two other morphological techniques that
have contributed in our lifetime. The first is phase contrast. I had a go at this in the late
1950s. The particular exponent of phase-contrast study of leukaemic cells in this country
was Pulvertaft,103 who was Professor of Pathology at the Westminster [Hospital, London].
In France, Dausset was working similarly on the subject and in Switzerland, Moeschlin. I
looked at their analyses of case series studied by phase-contrast microscopy to see what
proportion of monocytic cases they had found, which Pulvertaft had demonstrated to me
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in his lab very beautifully. Dausset didn’t find any among his analysed set, Moeschlin found
6 per cent, and Pulvertaft found 60 per cent, so it didn’t look as though one was getting
very much agreement on phase contrast.104
Finally, on to electron microscopy; a number of books have been written on the subject,
particularly by Tanaka and Goodman, by Bessis and by John Cawley, and me.105 Although
electron microscopy has contributed in a valuable way to learning about the nature of the
inclusions in leukaemic cells, I don’t think it has been of very much importance in terms
of classification. 
Goldman: Thank you very much indeed, Frank; that has been very interesting. I think it
leads almost straight on, because you dwelt for a while on monoclonal antibodies and other
techniques that Danny Catovsky has exploited, so I think if we could hear Danny and then
we will go on to David.
Catovsky: Thank you. Just an anecdote as it is an anecdotal day. I am a younger witness and
I remember attending a meeting in Argentina on leukaemia, where Professor Hayhoe was
speaking; I became a very great admirer of British haematology and that led me to come to
this country. I was also a great admirer of his early book on leukaemia,106 which I thought was
a masterpiece with its illustrations, especially the cytochemistry. I think the greater masterpiece
was his monograph that he quoted, resulting from the study from the Medical Research
Council on classifying the acute leukaemias by cytochemistry. It was a small monograph,
published by Her Majesty’s Stationery Office in 1964.107 I still regard it as a masterpiece on
the way the things were analysed, and on the material from the UK trials. From that time on
I became a very enthusiastic supporter of the value of morphology and the cytochemistry of
leukaemia and was lucky to have landed at the Hammersmith when David Galton was there.
In those days he also had a great interest in chronic lymphocytic leukaemia, which being a
form of chronic leukaemia is substantially different from acute leukaemia. 
At that time, John Dacie asked me to look at the myeloma cells that were in the same sort
of immunological pathway; David Galton had started an MRC trial in myeloma,108 and a
lot of slides and other material were coming through. That led me to study the
immunological aspects. The best initial development on the lymphoid leukaemias was the
distinction beween malignant B- and T-cells [I think the first report in the Lancet was by
Nossal, from Australia, who published a report showing that one type of lymphocyte had
immunoglobulin on the surface.109] Then almost at the same time, or very shortly
afterwards, people realized that another type of lymphocyte was forming rosettes with sheep
erythrocytes.110 Then we had to face up to the question of B- and T-cell malignancies. In
effect this marked the beginning of the immunological definition of the lymphoid
leukaemias, which was developed subsequently, as already mentioned, in the UK by Mel
Greaves and George Janossy, and by other people in the USA. Sen and Borella published
the first study recognizing T lymphoblastic leukaemia;111 it’s a very distinct form of
childhood leukaemia in which the blast cells form rosettes with sheep erythrocytes. They
realized that these leukaemias did not start in the marrow, because in these patients the
blood counts, the haemoglobin and platelet counts were normal, and very often they had a
mediastinal mass. Clearly it was with a sort of leukaemia/lymphoma starting in the thymus
and apart from that the cells had very distinct characteristics. We became very excited at the
time, and started looking at patients with high white counts with ALL. I remember going
to see one of our immunologists at the Hammersmith at the time, but he was reluctant to
embark on what he regarded as  rather applied research. We managed to publish in the
British Medical Journal on T lymphoblastic leukaemia; there were about four or five patients
presenting with very high white counts.112 I think one of them that I remember well was a
young boy, one of your patients, David. We also realized that these patients were mainly
teenagers who had developed the malignancy from their still present thymus. In the UK,
the topic was further developed by Mel Greaves and George Janossy. They examined
terminal transferase, the discovery of which was another major advance. In fact, McCaffrey
discovered it and I think that Victor Hoffbrand got involved in the early demonstration of
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the enzyme’s existence in the thymus gland. After that one could recognize lymphoblastic
leukaemia, where TdT or terminal transferase is positive and the myeloid leukaemias, where
terminal transferase is negative.113 That complemented the cytochemistry that was done
earlier, because cytochemistry was very good in deciding which of the leukaemias were
myeloid. The classification of the lymphoid leukaemias was not so specific at the time, but
then the sheep erythrocyte rosettes, terminal transferase staining and the common ALL
antigen allowed better classification of lymphoid leukaemias. 
The other point that I want to mention is that, even with those advances with the B- and T-cell
definitions and with cytochemistry, the classification of acute leukaemia was still very confusing.
Each group had its own nomenclature and it became a problem of trying to reproduce a reliable
classification of leukaemia as what would happen later in the field of lymphoma. 
One anecdote. In 1975, I had a fortuitous meeting with David Galton and Claude Sultan,
from Paris, and one of our American colleagues, John Bennett. It was decided to have a
small group that would permanently or regularly meet to review the morphology of acute
leukaemia. That group was the FAB (French–American–British) group. There were three
French, Claude Sultan, George Flandrin and Marie-Thérèse Daniel, two Americans, John
Bennett and Harvey Gralnick, and two British, David Galton and myself. We started
meetings where we just spent a week looking at slides down the microscope and discussing.
The idea was not to change things, but gradually to try to move things forward. Although
the FAB group did not change what the things were named, it defined them better and over
the years people gradually adopted the FAB-proposed nomenclature.114 This at least put a
stop to the problem of calling the same thing by different names. One of the major
achievements of the FAB group was that from 1976 onward they published about 12
papers; one of them became a citation classic,115 because everybody quotes it. I think even
now that this classification will be superseded by the new WHO classification. 
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Goldman: Just one question. What other diseases has the FAB group concentrated on apart
from the acute leukaemias?
Catovsky: Acute leukaemias first and then later on in, I think, the 1980s, it produced a
classification of the chronic lymphoid leukaemias,116 and myelodysplasia as well. Just as the
group was fading away, one of the latest papers was on the CMLs. One of the major
achievements, and I have to agree here with Frank Hayhoe, was that the cytogenetics came
in more or less as these things were developing and then we, the FAB group, started having
meetings with cytogeneticists. I remember attending several of the chromosome workshops
again in the 1970s with cytogeneticists, who were correlating cases and karyotypes,
meanwhile we morphologists were looking at the slides without knowing the karyotype. It
became apparent in some of these early studies that some of the leukaemias had very
distinct chromosome abnormalities. Promyelocytic leukaemia was very clearly shown to
have the t(15;17) translocation and so on. The rest is recent history. 
Hoffbrand: Since 1972 we had been measuring the immediate DNA precursors, the
deoxynucleotide triphosphates, in human blood and bone marrow cells. We set up the
assays at the Hammersmith Hospital in order to explore the DNA defect in megaloblastic
anaemia.117 We realized, after the publications of Fred Bollum, Mary Coleman and John
Hutton, that we could adapt the assay to measure terminal deoxynucleotidyl transferase
(TdT). Dr K Ganeshaguru established the TdT assay at the Royal Free Hospital in 1974.
Fairly soon after that Professor George Janossy joined the Department.118 We realized that
with a combination of different immunological markers and the TdT biochemical assay, we
could further characterize the acute leukaemias.119 The combination of these tests with
measurement of the transcobalamins, and Danny Catovsky’s cytochemical and lysozyme
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assays also enabled characterization of the myeloproliferative diseases.120 These studies,
together with those of other groups, led to an increased understanding of the origin and nature
of the leukaemic cell. One study showed close similarities between leukaemic cells and normal
cells at similar stages of development.121 They also showed subtle variations between leukaemic
and normal cells, for example, cross-expression of myeloid and lymphoid markers. They also
revealed the ontogeny of leukaemia cells and the cell from which each type of leukaemia
appeared to arise. The combined tests revealed new subtypes of acute and chronic leukaemia.
The use of combinations of markers also provided the first accurate tests for minimal residual
disease (MRD) in patients in remission.122 With Ken Bradstock, work was done which made
possible the detection of a single residual leukaemia cell, for example, a bone marrow cell
expressing both CD3 and TdT when the patient was in clinical and morphological remission
of T-ALL.123 This association with Mel, Danny, and George Janossy was extremely productive.
Galton: May I just follow on from Daniel, to pay tribute to the late Claude Sultan, whom
he mentioned, because it was Claude who persuaded us of the necessity for having a group
that turned out to be the FAB group?124 The point is that Claude had travelled and spent
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several months in various institutions in the USA and, of course, at the Hammersmith. He
spent quite a lot of time with us at Hammersmith, and he was struck by the fact that we
were all seeing the same cells but naming them in a different way. Frank pointed out that
there were many differences, even in neighbouring states in the USA, in the way they were
naming cells. Claude was particularly worried about the definition of a blast, because blast
cells were defined in totally different ways in the USA, in France, and in the UK,125 and he
asked, ‘What’s the use of trying to compare the results of treatment in various series, from
different countries, when you don’t know what they are treating?’ It was as simple as that.
That persuaded the FAB group to get on with it, and I think that Claude played an
enormously important part there. 
Another point. Daniel was talking about the Sternberg lymphoma, the T lymphoblastic
disease beginning in the thymus that used to be the province of radiotherapists, because
radiotherapy worked like magic – after a few hundred rads the tumour disappeared, you see,
but after a few months these young people always came back with a leukaemia. At that stage
they were sent to us, and we tried to persuade the radiotherapists that they shouldn’t start
with radiotherapy, because while they were irradiating the chest the cells were spreading to
the bone marrow and so on. I don’t know quite how we persuaded them to let us have a
new patient or two, but in the end we found that with chemotherapy you could get better
results, although of course they weren’t all that good. 
The last point relates to Frank’s mention of cytogenetics. I wonder whether people realize just
how the Philadelphia chromosome was discovered and why it was called Philadelphia
chromosome. There was a very busy MRC Cytogenetics Group in Edinburgh, headed by Bill
Court Brown. One of the people he had working there was Patricia Jacobs. At that time the
Unit as a whole was studying inherited conditions with chromosome abnormalities. That was
all in the air, but they had also been looking at some malignant cases, and she was studying
CML. She had six cases, in which she had noticed a tiny chromosome looking something
like the Y, and she realized these needed careful study, but there was immense pressure at that
time for the Unit to publish work on the inherited chromosome abnormalities. So she put
the slides in a drawer, meaning to get on with it in about six months’ time. Unfortunately, a
short paper from Nowell and Hungerford [from Philadelphia], describing this chromosome,
appeared in Science before she had time to look at them again. 126 Patricia was immediately
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able to correct one of their findings, because they only had two cases, both males, and they
thought it was an abnormal Y, but she had some males and females in her collection, and
she knew it couldn’t be a Y. She gave them the credit for the first description by naming it
Philadelphia chromosome.127
Goldman: It was, in fact, named Ph1 in recognition of the probability, the thought that
there would be further specific abnormalities.
Galton: She thought this would be the first of many. 
Goldman: Let me give you a personal point of view about the topic that I know too well,
perhaps, and others in the room, but not everybody, also know very well and that is to take
up the story of the Philadelphia chromosome and end with STI571 (imatinib), which was
licensed for clinical use on Thursday of last week.128
The story for me starts, I think it was 1974, when I was attending a meeting in Poitiers on
the involvement of chromosomes 9 and 22 in leukaemia.129 The stars present were, of
course, Janet Rowley, Joseph Tanzer and Sven-Åge Kilmann. I remember very well Sven-Åge
Kilmann saying to Janet Rowley deliberately, directly to her, ‘You are going nowhere, you
are just stamp collectors’, a famous statement directed at the cytogeneticists in those days,
but of course she wasn’t just stamp collecting at all. 
I think the next important development in that story was the publication in 1984 of a paper
from Grosveld’s group in Rotterdam on the BCR [breakpoint cluster region], which was the
clustered breakpoint in 19 different patients with CML.130 He, Groffen and Heisterkamp
showed very elegantly that the breakpoint on the Philadelphia chromosome in different
patients with CML was clustered in the 5.8 kb region. 
The next five years was a period of very exciting and rapid development that David and
others will remember well, with the characterization of first the juxtaposition of the ABL
protooncogene with the BCR sequences and then the characterization of the BCR gene. 
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In 1986 I spent a period in the Whitehead Institute for Biomedical Research that is
attached to Massachusetts Institute of Technology in Cambridge, Massachusetts. There was
a young PhD student who was an extremely enthusiastic student of David Baltimore’s, and
his project, which seemed at the time ambitious but still completable, was to put the
BCR–ABL fusion gene into murine haemopoietic stem cells, murine progenitor cells, and
so to simulate CML in mice. George Daley’s paper, as some will know, was published in
Science in 1990,131 and I think for almost everybody, it set the seal on the belief, or the
conviction, that the BCR–ABL fusion gene was the proximate cause, the major cause, of
the chronic phase of CML. 
A lot of ‘i’s were dotted and ‘t’s were crossed in the next ten years and it is certainly not
appropriate to go through all the many pieces of additional data that accumulated, but round
about 1995, an ex-colleague of mine, whom Ray Powles will probably remember, John Ford,
called me up to say they had a new compound that was active in blocking the kinase activity
of the ABL protooncogene and, ‘Was I interested in studying it?’ I said, ‘Yes’, without any
hesitation. Meanwhile, Brian Druker in Oregon had worked together with the chemists at
Ciba Geigy to develop this compound and published in 1996 that it was very good at
suppressing the survival of CML cell lines and CML progenitor cells in vitro.132 In 1998 this
compound entered clinical practice in the USA as treatment for CML. Initially, I think many
people, including Brian Druker, were highly dubious as to whether it would have any effect.
In the event, it has proved over the last 18 months that the administration to patients of this
compound that was made by Ciba Geigy in the early 1990s is highly effective, given by
mouth, at inducing haematological control in patients with CML and in more than 50 per
cent it induces a major or complete chromosome remission.133 It is much better than alpha-
interferon in those regards and, of course, it’s much less toxic. 
The new pharmaceutical company, Novartis,134 submitted papers for registration in the
USA to the FDA in February of this year; they submitted to the European authorities at the
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same time, and about four days ago, Thursday of last week, the FDA formally announced
that it had approved the use of STI571 [signal transduction inhibitor] for treatment of
CML.135 This is thought to be the most rapid licensing of any drug in oncology by the FDA
within the last 25 years. ASCO, which is usually a moderately boring meeting, today was
apparently transformed by the news of the STI licensing. So what’s the moral of the story?
The moral of the story simply is that here is a very elegant example of the translation of our
understanding of what is literally the molecular biology of a form of leukaemia into therapy.
There are other examples I know, such as the use of all-trans-retinoic acid for treatment of
M3 acute leukaemia, the targeting of other kinases and I think there are other good examples,
but possibly none as elegant as the one I have just recounted. I think there is little doubt in
my mind, let me rephrase that, I very much hope that as we enter the twenty first century,
we will see the end of the era of non-specific cytotoxic drugs designed to cure leukaemia –
and they have undoubtedly been effective to some degree in that regard – and we will see the
innovation, the instigation, of the era of so-called targeted molecular therapy for leukaemia.
That was just a sort of personal reminiscence really. I have had the privilege of being a close
observer and have been involved to a minor extent in this story, and it’s been great fun. I don’t
think that needs a discussion unless anybody else has something to add particularly on that
topic. It’s not even proper history – it’s recent history rather than distant history.
Hunter: Just one very small ethical note to say about that. Novartis has announced that the
drug is called Gleevec or Glivec,136 according to which side of the Atlantic you are on, and
they are going to market it, pricing it according to the financial means of the patient being
treated. 
Goldman: We want to switch our attention now. We have talked a little bit about children,
but I want to return to ALL in children. I am going to ask John Lilleyman to open and then
I think Humphrey Kay would like to make some comments. 
Professor Sir John Lilleyman: Thank you very much, John. I have to say it’s an increasingly
rare pleasure for me to attend any meeting where I don’t skew the average age upwards, and
I do feel a very junior witness here since I have only been in this game for just over 30 years,
and therefore you will have to forgive me. Talking about the history of childhood leukaemia
and the treatment of it means that we have to look back over 50 years. So for the first two
decades of this, I am going to have to ask Humphrey, who is my mentor, to mark me out
of ten and correct me where I go wrong. I am not going to talk about it very much because
I hope he’s going to fill in the gaps. We are talking about the history of the treatment of
childhood leukaemia in the UK. We have first of all to be clear that we are talking about
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the treatment of ALL, a rather irritating tautology, since there’s no chronic lymphoblastic
leukaemia, but by common practice and usage that’s what we call it. This, of course,
accounts for some 80 per cent of all childhood leukaemias and is the most common
malignant disease in children between the ages of 1 and 10. It’s an extraordinary story, the
treatment of childhood ALL, and it begins with the seminal publication we have already
discussed by Farber and colleagues on the use of aminopterin in 1948.137 The year 1948 was
also important in this country, because it marked the establishment of the National Health
Service, which also has had an influence on the development in this country of treatment
of malignant disease in general, and childhood leukaemia in particular. If we take the five
decades, these are quite useful chunks of time for us to look at the various stages of the
evolution of the treatment of childhood leukaemia. We have to start by saying that before
1948 there was little treatment, I won’t say nothing, in the way of treatment, because of
course there were always transfusions and antibiotics available at least from the mid-1930s
onwards.138 To find what actually happens to children when you do absolutely nothing, you
have to go further back than that, and the earliest case report that I have found is in the
Lancet in 1884.139 I presume that case reports in the Lancet even in those days were fairly
unusual cases, so this must have been fairly remarkable for its time. It describes a five-and-
a-half-year-old boy who’s admitted with fever and pallor, and tachypnoea. He didn’t have
organomegaly that they could discover and his history was of gradual onset over six weeks.
He survived for only 11 days following his admission into hospital and he got increasingly
unwell with pallor and tachypnoea. The fascinating thing about this is that his blood was
examined three days before he died, and the only comment in this case report is that there
were three white corpuscles for every one red corpuscle. Just to save you the agonizing
mental arithmetic, I looked at this and of course you don’t know what his white count is,
but assuming it was, say, as high as a million, that would mean that his haemoglobin would
be of the order of 1g/dL when he actually perished. That’s what happens if you do nothing.
Children die within a few weeks. They die in about three months if you support them with
transfusions and antibiotics and, of course, now we have reached the stage where if you take all
children with ALL, the long-term event-free survival for the whole group, would be of the order
of 70 per cent.140 We have gone from that to that in 50 years. The original paper by Farber
actually studied 16 children, and it must have been remarkable at the time to be around to see
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the effect that it had, where it describes moribund individuals going into complete remission.
STI571, as we have just heard, is pretty dramatic, but this must have been even more dramatic.
Yet doctors were severely criticized for meddling with children who would all relapse and die
eventually and so the ethical debate went on for quite a long time. Paediatricians are a fairly
conservative bunch generally, particularly in the UK, and they were fairly slow to take up the
challenge to treat children with this condition, particularly when the word ‘cure’ hadn’t come
into the debate, and didn’t come into the debate for some years after that.
There were one or two interesting diversions and I don’t know whether they were British or
not, but I came across an interesting article that, of course, is historical for me; it may
actually be contemporary for others, certainly David Galton perhaps, as I think he was in
the original group.141 There was an MRC group that looked at the use of ACTH and
cortisone in various blood diseases. I think they took 88 patients with a miscellany of blood
disorders that were taken at random out of any haematology textbook and gave them
ACTH or cortisone, of whom 20 were children with acute leukaemia. Of those I think four
were noted to have some response, and I think that might have been one of the very earliest
descriptions of the response of childhood leukaemia to steroids.142
The next most seminal publication after the 1948 Farber paper was probably the 1953
Burchenal paper, looking at 6-MP, which had been developed by Gertrude Elion and
George Hitchings, and for which they got a Nobel Prize.143 That, of course, gave us three
very useful drugs: the folic acid antagonists, the purine analogues and steroids. Then the
vinca alkaloids came in towards the end of the 1950s. The interesting thing about the vinca
alkaloids was that they came in around the time that there was this huge burst of scientific
clinical activity at the National Cancer Institute, where they noted that if you gave
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vincristine with the myelotoxic drugs that we had been using so far, you didn’t get
synergistic myelotoxicity, but you did get synergistic tumour toxicity. This was the birth of
combination chemotherapy.144 The history of the treatment of childhood leukaemia is
written large in the annals of oncology in general. 
Of course, platelets came in towards the end of the first decade. If we are talking about
1950–1960, the very first reports of platelet transfusion did creep in at the end of that time.145
I think the position of the UK in the first decade was mostly to watch the Americans, and
not doing much, but there were one or two children who were treated with the single agents
around at that time who are long-term survivors to this day. Most units that dabbled in this
have got such patients, although, as we have heard earlier, the diagnosis might have been
wrong. In fact, where you can go back and look at this, the diagnosis was usually right.
There have been one or two patients who have had very late relapses, where the disease is
clearly the same as it was at diagnosis. I do remember one of the first patients that I became
involved with, who had been looked after by Professor Ronald Illingworth, a paediatrician
of some renown in his day. He treated this boy with daily oral methotrexate for about ten
years, because no one knew when to stop – there were no guidelines. Eventually he did stop,
the boy was well and his leukaemia never came back, but he eventually died in his early 20s
of oesophageal bleeding from fibrosis of the liver, probably induced by the methotrexate, so
that was a bitter–sweet story. 
Going into the 1960s and 1970s, the next major milestone as we have already heard was
the St Jude’s story: Don Pinkel’s vision to come up with this idea of total therapy by looking
at all the nooks and crannies, getting the disease to go away, consolidating it, and then the
inspirational stroke of giving maintenance chemotherapy.146 Maintenance chemotherapy is
a peculiar notion; it flies in the face of all basic oncological principles and the strange thing
about the commonest type of lymphoblastic leukaemia is that for some reason it needs a
long prolonged phase of this basically immunosuppressive chemotherapy. Nobody quite
understands what this therapy is doing, but Pinkel’s original rationale was based on the
observation of tuberculosis and the idea that the cycling time of the leukaemic blast cell was
roughly analogous to the tubercle bacillus, and so the notion of giving maintenance
chemotherapy was based entirely on this idea of long-term chemotherapy for
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tuberculosis.147 Whatever his reasoning, he did the right thing at the right time, and as I say,
childhood ALL to this day remains the only human malignancy that I am aware of where
this type of therapy is not only effective but essential. I think it was dear old Tim
McElwain148 who said that the worst way to treat cancer is to dribble in little bits of
chemotherapy over a long period of time, which is precisely what you do when you treat
childhood ALL with maintenance treatment. So what that’s doing, we really don’t know. 
We started at this time to have some ideas of our own in the UK and we have heard about
the Concord trial that was a joint Anglo–French venture run by the increasingly popular
MRC-based UK group and the French.149 This was slightly less successful, perhaps, than the
aeroplane, with which it was co-named, because that was being designed at about the same
time. Humphrey will correct me if I am wrong, but it did one very useful thing. It
highlighted something that hadn’t been focused on, and that is maintenance treatment;
because it was a three-way randomization for immunization versus nothing, versus
maintenance, it was possible to show that it was, above all, maintenance that made a lot of
difference and improved things. Giving immunotherapy and giving nothing was about the
same. There are very few randomized trials that actually show the effect of maintenance
treatment. The only other data on this came from the West German group much later on,
where they tried to drop maintenance. Most of the children relapsed, and as they were
perhaps ashamed of it, they never actually published it. But that’s another story.150
That takes us to the 1970s and 1980s, and I am getting onto slightly more comfortable ground
here, because I am talking more from personal experience now, so Humphrey can relax a little
bit. This was the sort of zenith, I suppose, of the MRC working party that was very much led
by Humphrey as Secretary, although he never chaired it, as far as I recollect. There was Professor
Hutchinson first of all; then there was Roger Hardisty, and then I think Tim McElwain after
Roger. Humphrey was the driving force behind it and under his stewardship we launched the
series of UKALL trials.151 They were based on the St Jude template and they were trying the
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addition of this, or the subtraction of that, but during the 1970s we had UKALL I, II, III, IV
intensive, V, and VII.152 We had quite a lot of trials, but not huge numbers of patients, and we
learnt quite a lot about how best to give maintenance therapy. We learnt that alkylating agents
didn’t seem to offer very much in routine therapy. We did notice that boys didn’t do as well as
girls, which sent us off down a blind alley for a long time, thinking that the testis was a
sanctuary site and we had to do something with it, like irradiate it. But I digress. 
Taking us to the 1980s very quickly. What was happening at this time was that whilst we
were getting organized and getting children into centralized randomized clinical trials in the
best traditions of the MRC, the results that we were getting weren’t quite matching up to
those that were being obtained overseas by apparently similar protocols. This puzzled and
worried us. So what we did in 1980 was to take a Children’s Cancer Group (CCG) protocol
from the USA, word for word, comma for comma, and applied it in the UK simultaneously,
with the cooperation of the CCG. The first thing that we noticed was that it was much,
much more toxic than anything we had used before, despite the fact that on paper it looked
very similar. The reason was that the protocol was much more prescriptive and did not allow
the clinician the freedom to stop treatment when children got a little bit poorly. We pressed
on and I have to say that we did lose some children, because we weren’t aware of the toxic
side effects of this treatment, but once we got the hang of it, we produced the biggest single
increase in overall event-free survival in this country. It was about a 20 per cent jump from
the previous cohort studies to this one, UKALL VIII, that ran from 1980–1985.153 We have
never explained the reason for that jump, but we suspect it’s something to do with physician
compliance with the protocol and sustained chemotherapy, both in the consolidation phases
and the maintenance phases, but that’s still an open question. The West Germans were
producing much better results than we were, although they weren’t doing it on a randomized
trial basis – they were just doing cohort studies and producing better overall survival figures
than anybody else, and in the sort of Teutonic way that they have, were saying, ‘This is how
you should all do it’. Eventually they persuaded people, their theories were put to the test of
the randomized trial by both by the Americans and us, and we confirmed that what they said
was correct while they just sat there with their arms folded and said, ‘Well, we told you so’. 
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But now what’s happening since the results of treatment of all groups are improving, is that
it’s getting increasingly difficult to be confident about a real improvement in outcome, and
so the randomized trial is actually having a renaissance and, not only that, we are having to
look to international collaboration to get the numbers of patients to achieve the statistical
power to answer the current questions that remain. We have still got a long way to go, but,
as I say, overall survival ever since chemotherapy began has never been zero, but 5, 10 per
cent, even, with single-agent therapy, 20 per cent with the early combined therapies,
through 30, 40, 50 per cent, and we are now somewhere up at 60–70 per cent. We have
caught up with the rest of the world in terms of our results in the UK. We are not ahead of
the game, as we are with childhood AML, but that’s another story that I haven’t got time to
go into. For childhood ALL, we are now all at the same level, looking to international
collaboration. The MRC Childhood Leukaemia Working Party played a very pivotal part in
that and pivotal to that working party was Humphrey Kay, who will now comment.
Goldman: Before we go to Humphrey I have one question. Peter Hunter, do you want to
comment on 6-MP, because John did mention it briefly? 
Hunter: Briefly, I feel the intellectual background behind the discovery of the antileukaemic
action of 6-MP in 1952, should be mentioned. In 1940, two ground-breaking papers by British
experimental pathologists appeared and established that the antibacterial action of
sulphanilamide was due to a blocking effect on bacterial multiplication, caused by competition
with ‘an essential growth factor’, para-amino benzoic acid (PABA). Sulphanilamide and PABA
had closely similar but subtly different structures, i.e. they were analogues. Paul Fildes suggested
that the drug might occupy the substrate binding site on an enzyme and prevent the enzyme
from functioning. The Woods and Fildes’s hypothesis suggested that a rational approach for
research in chemotherapy would be to synthesize analogues to specifically targeted molecules.
This idea was taken up in 1942 at Burroughs Wellcome in Tuckahoe by George Hitchings. His
remarkable research strategy used the Woods and Fildes’s hypothesis but focused it on analogues
of the purine and pyrimidine constituents of DNA. The system that he chose to detect biological
effects of these analogues, was a culture of Lactobacillus casei. By 1951 his colleague Dr Trudy
Elion had synthesized and tested over 100 purine analogues. This led them to try 6-MP as an
appropriate animal disease model at the Sloan Kettering Institute, where they had been
cooperating with Rhoads since 1947. 6-MP was found to be of high efficacy and relatively low
toxicity. Regarding the financial mechanisms that facilitated 6-MP’s discovery, it is interesting
that their laboratory was for many years partly financed by the Sloan Kettering Institute, despite
the fact that it was in Burroughs Wellcome American research headquarters.153a
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Goldman: Now we rely on the reverse – drug companies funding hospitals. Humphrey, let’s
return to children’s ALL.
Kay: Can we start at the late 1960s, when we had created, at the newly built Marsden
Hospital at Sutton, a new unit where it was possible to give intensive treatment and hope
that the patients wouldn’t get infected, and we could give them platelets and so on? At that
point, we were visited by Leslie Witts, who had been in charge of the MRC trials, and had
despaired of getting a childhood leukaemia trial going. The reason for that, looking back,
was very clear. It was a subject that was one of rapid progress and unless you had a lot of
patients in your intake, you couldn’t complete a sufficient number before people wanted to
do something different, as indicated elsewhere. In order to get a sufficient number of
patients, we more or less had to cover the whole of the UK, and it was quite easy as a matter
of fact, through persuasion and diplomacy, to induce most of the major centres throughout
England, Wales, Scotland and Northern Ireland to put their patients into an established
protocol. There were various ideas at that time. Intensive therapy with combinations such
as VAMP [vincristine, amethopterin (methotrexate), 6-MP, prednisolone] were on the
market, but we were most attracted by Georges Mathé’s claim for immunotherapy. Had we
looked a bit more carefully, we would never have done this trial at all. He had claims for
eight long-term remission patients. However, if you look at it, first of all there was no record
of what previous chemotherapy any of those patients had had. The immunotherapy they
had consisted of either Pasteur BCG, irradiated leukaemic cells, or both BCG and cells, so
there were three different treatments, resulting in long-term remission. We thought we
ought to try some sort of immunotherapy, and we asked Colindale154 about the Pasteur
BCG, which they said was an inconsistent product, sometimes contained other
microorganisms as well, and it was doubtful that they would be able to supply enough. We
went for what we could get as a standard product, the Glaxo BCG, and as John Lilleyman has
said, it did have this one valuable result that showed that if you continued your maintenance
treatment, patients did better than if they had no further treatment or immunotherapy. We
had, in a sense, a positive result, but we quickly abandoned immunotherapy at that time, and
started on a series of UKALL trials comparing various regimens, length of treatment, CNS
prophylaxis and so on. I don’t think we were ever very innovative, and from that point of view
I have to say that the stimulus came from Donald Pinkel in Memphis and later from Riehm
in Germany, who had more intensive treatment. I think at the beginning we couldn’t have had
those intensive treatments, because I don’t think there was either the expertise or the facility
in all the centres throughout Britain to do that. We would have lost some children as a result
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of the treatment. Nevertheless, we had these comparisons and I think, in some ways, the most
valuable part of it was that there was a discussion of the protocol before and during, and
people learned from others what the snags were and how you should manage the patient at
each point in the regimen. That was one valuable thing. 
The next valuable thing was that we were able to provide Mel Greaves with a large supply
of leukaemic blood cells, so that he could do his characterization and distinguish common
ALL, B-cell and T-cell diseases.
Later on still the cytogeneticists came in and there is now this wonderful monograph by
Lorna Secker-Walker on the chromosomes of ALL,155 which I think would have been much
more difficult to compile if we hadn’t had trials going throughout the 1970s and 1980s.
Anyway we did manage to get acceptable forms of treatment. 
We did find a few snags and another value of the trial was to pick out toxicity. A particular
one was methotrexate neurotoxicity. That came up in the course of a conversation one day,
when one haematologist had a patient in his centre with neurotoxicity and another clinician
said he also had one, and somebody else said that they had one as well. In no time there
were seven cases that we could write up. It was because you had a group discussing the
whole thing that it was possible to identify that complication. 
One other thing, which I am sorry we never emphasized because we were rather under the
control of the statisticians, who wouldn’t accept anything unless it was significant at a
particular level, is that those weren’t necessarily the most interesting comparisons. The thing
I noticed at one stage was that the two Scottish centres, Edinburgh and Glasgow, were
getting the best results of the lot. When you looked at the case records, it was because they
were seeing their patients more often. Whereas in England, for example, they were seen
every fortnight, in Edinburgh and Glasgow it would be every week, and later every fortnight
in Scotland and every four weeks in England. I am sure that had two effects. It enabled them
to regulate the dosage better, keep it up to the maximum tolerated and probably also
induced a better measure of compliance by the parents, because I am sure, in the early stages
at least, compliance failed here and there. Now how did they do it? Well I became aware in
the 1980s that the Scottish Health Service, is a lot better funded than the English Health
Service. I actually had a figure last week and they are 23 per cent better funded than we are
in England, and I am sorry that we didn’t make the point when we published some of these
results. There was another example at the same time, which was that when we were doing
transplants and we wanted cytomegalovirus-free blood, the Scottish transfusion centres
could provide it and all the English centres said they couldn’t afford to do so. I do think that
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that should have been published. If you believe, as I do, that our health service is
structurally very good, but has been seriously underfunded for 30 years, it would be very
nice to find other examples and publish them. 
Goldman: Humphrey, that’s very interesting, especially your emphasis on the impoverished
nature of England compared with Scotland.
Professor John Walker-Smith: I came to Bart’s in the role of a general paediatrician in early
1973. I remember very vividly coming to that dynamic unit with Gordon Hamilton Fairley
and Jim Malpas. There was one great difficulty for the compliance with these very tough
regimens, and this was the conservative view of some of the nursing staff, who made it
particularly difficult for the consultants. 
You mentioned the UKALL trials. I think these trials helped enormously in many ways.
Once these trials were underway it enabled the consultants to encourage the nursing staff
that it was absolutely vital to stick to the protocols as a great way of improving care. Prior
to the introduction there was tremendous pressure on the consultants at times to
moderate the regimens on an individual needs basis. The UKALL trials led to much
better nursing compliance. 
Goldman: That’s a very good point. These last few minutes were meant to be on ALL, and
we have merged it with MRC clinical trials, to which we are coming in more detail. Is there
anything that people would like to raise on ALL, the treatment of ALL specifically in
relation to what John and Humphrey have been talking about?
Dr Rosemary Shannon: I think quite rightly we have put a lot of emphasis on the drug
treatment of leukaemia, but I think there are other factors that have also contributed and
certainly made life easier for the patients, like the introduction of central venous lines that
I think we haven’t mentioned, and the use of prophylactic Septrin (co-trimoxazole) and
better antibiotics and blood products. Certainly I think one should pay tribute to the
introduction of specialized nursing, because that’s revolutionized the lives of some of the
patients, actually. 
Goldman: You make some very good points. Supportive care and specialized nursing, and
specialized medical practitioners. Remember, if you go back enough years, Bodley Scott was
an example of a superb general physician who had a major interest in haematology, but as
far as I know he was never trained as a haematologist. I think he was trained as a general
practitioner. Isn’t that right, Ray? In other words he trained himself, and of course to a large
extent David and others did.
Powles: Bodley was indeed the finest general physician I ever met; one of his patients was,
of course, the Queen. 
Leukaemia
51
Crowther: I understood that he did his MD thesis in the 1930s, on the role of bone
marrow examination as a useful tool in haematology.156
Goldman: I think we slightly more modern haematologists sometimes forget that
examination of the bone marrow by aspirate came in only in the 1930s. Is that right, David?
Booth: Let me just quote John Dacie, with whom I had tea on Tuesday, saying he
introduced aspiration biopsy to Manchester, when he worked with Wilkinson in 1936. 
Shannon: One thing I didn’t mention was the introduction of the measles vaccine. I can
remember being taught in my early career as a paediatrician that measles was an important
cause of death in children on chemotherapy. In my entire career as a consultant I have yet
to see a child with measles, so I think there were other factors that were running in parallel
in the general health of children at the time.
Galton: I just have two points to make. One is that a little earlier on, one of you, and I have
forgotten who, referred to the problem that arose in the 1950s and 1960s when children
were being treated with some modest success, and a few of them appeared not to be
relapsing.157 How long did you go on with their maintenance therapy? This used to be a
topic in which at international conferences interested haematologists would meet privately
and discuss how many patients they had who had been on either long-term methotrexate,
or 6-MP, five or even ten years. Was it safe to stop? Nobody knew. 
Then in 1970 or 1971, I visited Mila Pearce, who was head of the Leukemia Group A, I think,
in the USA, and whom I had met many years earlier, when she was at Great Ormond Street.
She pointed out that they had made very careful observations in Leukaemia Group A studies
and they were pretty convinced that you needn’t go on beyond five years. I don’t know whether
that was ever published, but she was very certain about that. So I was able to take off a number
of patients who had had their five years, and as far as I know very few later relapsed. 
Goldman: But you wouldn’t treat for five years today would you John?
Lilleyman: No, we still don’t know what the optimum time is for maintenance therapy,
despite having done several randomized trials to try to find out, and even a meta-analysis.
In general it seems that the longer this treatment goes on, the less likely patients are to
relapse and the more likely they are to die of treatment. When those risks balance each other
is very difficult to define, but presently, just to be logical about it, we are treating the boys
for three years and the girls for two years.
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Galton: A second point about poor funding from the NHS. Now that may be true in a
major sense, but the authorities weren’t oblivious to this. For a good many years the then
Department of Health and Social Security (DHSS) used to send a representative to all our
MRC steering committee and working party meetings, and there came a point where it was
quite obvious that some of the centres couldn’t possibly give the intensive – well, it was
intensive for those days – treatment that they were supposed to in the protocol, without
more nurses. The person who came from the DHSS reported this when he got back to
headquarters, and in fact for a number of years centres that needed extra nurses, if they had
enough patients, could get financial support. I can’t remember how long this went on for,
but it was certainly helpful to the trials.
Goldman: I don’t know if it still goes on. In a few moments we are going to ask David Grant
to comment on funding leukaemia research and leukaemia therapy in this country. But
before we do that I think we should address specifically the issue of other MRC trials, and
I think the main person I am going to ask is Ian MacLennan, but also I think David might
like to comment and Humphrey might like to comment afterwards. Ian, would you like to
open the topic of MRC clinical trials?
Professor Ian MacLennan: The MRC trials, particularly those on the acute leukaemias,
have been extraordinarily successful. The proportion of patients with any type of cancer that
get into trials is usually well under 10 per cent and often only 1 or 2 per cent of patients
with certain cancers get into trials. This contrasts with the majority of people with acute
leukaemia in this country getting into an MRC trial; in some cases this is the overwhelming
majority of patients. I do not think one can underestimate the educational role that the
MRC’s trials have had in increasing the standards of the treatment in the UK and bringing
forward new treatments. The MRC has largely conducted randomized control trials. Often
these have not been large enough, but sometimes they have. I would like to highlight one
or two examples where they have been successful and informative. 
When I first came into the working party on leukaemia in adults in 1971, the results of the
latest AML trial showed a median survival of six weeks. Derek Crowther has been telling us
about the Bart’s experience. This inspired the MRC to carry out a phase III immunotherapy
trial; John [Goldman], you will remember that, in the early 1970s. At that stage different
centres were getting remarkably different remission rates using what was then called the
Bart’s 3 regimen, which was DAT 1 plus 5.158
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The differences in remission rates between the centres was almost entirely due to differences
in  supportive care. Frank Hayhoe and John Rees introduced the escalation of that DAT
regime, going from 1 plus 5 to 2 plus 7 and then 3 plus 10.159 They produced one of the most
startling results from any controlled trial. Provided the platelet transfusions and the
antimicrobial treatment that were available by that stage were used, patients spent a shorter
period in hospital, if they had the more intensive chemotherapy. In addition, remission rates
were better.160 This was a really important result and it was hard evidence that allowed one
to bring forward intensive chemotherapy in subsequent studies. I think it’s also worth
remembering in relation to AML that in the early 1970s there was a strong debate as to
whether it was ethical to treat people with AML at all.161
If I can go back on to the childhood leukaemia trials. There was an unfortunate policy for which
I was not entirely blameless, in which there was an aim to try to minimise treatment-associated
toxicity in childhood leukaemia. We identified where during treatment patients were getting
measles, encephalitis and interstitial pneumonias. These previously had been rare diseases in
children. The treatments were modified to reduce toxicity at the time of maximum risk of these
complications developing. This unfortunately also reduced the anti-leukaemic efficiency of the
treatment. Eventually it became clear that the gentle approach treatment was giving sub-optimal
results. More intensive therapy was given and physicians learned how to manage toxicity.  
Intensification doesn’t always work and I am going to give another trial example illustrating
this. In the MRC first myeloma trial162 it was realized that many patients with multiple
myeloma were dying from renal failure. At least one-third of the patients in this trial
presented with renal failure that persisted despite an initial period of hydration. The
conclusion was that the light chains of T-cells were causing the renal failure and that, of
course, is correct. This conclusion was used as a rational, in the third trial, to test whether
the renal failure could be reversed by removing the light chains by giving intensive
chemotherapy. This approach was associated with early mortality in most patients given the
intensive therapy. Analysis of the pathogenesis of renal failure in multiple myeloma showed
that in most instances it was secondary to a selective proximal renal tubular defect cased by the
presence of light chains. This caused fluid loss, which predisposed the patients to renal failure.
The selective nature of the defect was shown by patients still able to reabsorb glucose and some
low-molecular weight proteins from the glomerular filtrate. Based on these studies a regimen
using a sustained high fluid intake was introduced for managing and preventing renal failure
in patients with multiple myeloma. This has been successful in a high proportion of patients.
Using this approach the median survival in the third trial of 37 days for patients presenting
with creatinine levels of about 200 µm/L, was extended to more than  18 months in the fourth
trial. Relatively few patients with multiple myeloma now die of renal failure.
Those are just one or two examples that illustrate the success of  the MRC trials. Again I want
to emphasise their important educational role. The new cooperation with the cancer funders
and the Health Service, and the formation of the National Cancer Research Institute, offer a
very real possibility of getting high numbers of patients with other neoplasms into trials. It is
important that good phase I and phase II trials are run by specialist centres and groups, for
these feed the multi-centre phase III trials. The leukaemia trials have worked well because
there have been strong centres doing phase II trials.
Galton: The MRC trials were brought up at a meeting of the MRC Cancer Committee in
1957, at that time under the chairmanship of Lord Cohen. It was recommended that a
working party should be set up to start trials as soon as it was practicable, and the next move
we have already heard about from Frank, was the setting up of this typing committee to
show how impossible it was at that time to try to allocate treatment according to the type
of leukaemia, because we didn’t diagnose them properly. When the Working Party was set
up it was not specifically for adults or children, but it was, I think, mainly for adults at that
time. That working party began its work in 1959. 
The first trials were extraordinarily primitive, and the results rather difficult to interpret. They
weren’t very good, but they did show just about a glimmer of hope and that led to their
continuation. I must say that the most significant point about the early trials was the way in
which the statisticians were involved. The first meetings were attended by Sir Austin Bradford
Hill and Sir Richard Doll; it’s a great, great pity that he and Richard Peto aren’t here today,
because they helped to provide a proper framework in which these trials could be designed and
statistically analysed. I know that Humphrey was a little bit disparaging about their role in
some of the children’s trials when he spoke a few minutes ago. I didn’t have much to do with
the children’s trials; all I can say is that the statisticians have been and still are an absolutely
amazingly efficient group of people. The trouble they take is immense, their efficiency is
terrific, and I was tremendously impressed from the start by the trouble the young disciples
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of Richard Doll and later Richard Peto were prepared to take, to understand something about
the disease. I remember Richard Peto came in 1964, when we had the first myeloma trial, and
I showed him X-rays of myeloma patients, case histories, told him about immunoglobulins
and showed him slides; he got to know a lot about myeloma. The same was true of the
statisticians who became involved with the leukaemias too – they were absolutely essential and
I think everybody concerned with today’s trials will confirm what I have said.
The other point that I would like to make very briefly, is that several people have already
referred to the first group of trials in AML, and I can say that the major trials that have
yielded results were those that were started in 1970. Before that, rather feeble combinations
of drugs were used, but 1970 was the first of a series on multiple-drug therapy. One of the
good things about the early trials was that one arm was kept from one trial to the next, and
in fact the one that survived the longest was the one we have heard about; it was devised at
Bart’s and became known as Bart’s 3.163 The point of great interest was that in successive
trials the Bart’s 3 regimen results got better and better and this, Richard Peto always said,
was the best evidence necessary to show that randomized trials were the way to find out how
things worked. Historical controls were useless, because you would have the Bart’s 3 effect
claiming successive new treatments to be better, which were not better at all. It was probably
because of the improved experience of the physicians involved and their increased
confidence in giving the regimens exactly as specified. Unfortunately, J Freireich164 is not
able to be here this afternoon. He, of course, never did controlled trials, he didn’t believe in
them at all, so it would have been nice to hear what he would have said.
Goldman: Freireich would certainly have given you a spirited rebuttal at that last point.
Derek, do you want to comment on Bart’s 3 at all?
Crowther: Not really, apart from saying that all the Bart’s studies were small, with relatively
small numbers of patients. I think that we treated about 70 patients with AML on the
original five-day regimen, before moving on to Bart’s 4, and so on. The previous results in
our own practice using single agents were terrible. They all died and I don’t think we had
anybody who went into complete remission. However, I do remember that we had one
patient at Bart’s who had been treated in the 1950s with continuous 6-MP, for just a three-
month period. This patient went into complete remission, and stayed in remission as far as
I can remember, for about 20 years. The pathology was looked at again and the diagnosis
was confirmed. With the new combination chemotherapy the whole team could see that the
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majority of patients were returning to normal health. If J Freireich had been here he would
have pointed out that when he came to London in the early 1970s, he said that he thought
that ‘remission induction’165 for patients with AML was no longer a problem, but we had to
learn how to treat patients in remission and how to keep them in remission. We did terribly
badly with that and nearly all the AML patients I treated at Bart’s eventually died. We had
very few long-term survivors in those early trials, although we did have a high complete
remission rate.
Goldman: Humphrey, would you like to comment on clinical trials from what you have heard?
Kay: I am very sorry Richard Peto isn’t here. He and I had fairly profound differences, and
I have been looking back at an article I wrote in 1983 and I think that most of the points
I made are still valid.166 The question is whether you need total randomization throughout
all multicentre trials. The fact is we have had a number of trials in which there has only been
partial randomization, the polycythemia trial is one and UKL 6 and 7; testicular irradiation
was one some centres went in for and others didn’t. I think you can get away without total
randomization throughout the whole time. 
Then there is the question of whether you are comparing results of treatment, or treatment
policies, because what the statisticians tended to say was that you can only compare
treatment policies; if you can’t continue with a treatment, that’s a failure. Now I think that
is a mistake. There are instances, the one I took was the myeloma 3 trial, in which you had
either cyclophosphamide, relatively non-toxic, or melphalan plus prednisolone, and the
difference between the two in aggregate was not significant. However, if you looked at the
results, you could see that in the ones on melphalan plus prednisolone, some patients
developed severe myelotoxicity; clearly that was an inappropriate treatment for them, but
for those who could tolerate it, they did better than the cyclophosphamide patients. You
mustn’t just compare treatment policies – you must compare tolerated treatments – and
that’s something that doesn’t appear in any of their articles. David said something about
comparison with the previous best or a standard treatment and, of course, that can work
both ways; but one way it can work is that if you know all the snags in an existing treatment,
your patients may do better, because you know how to avoid those – you don’t know how
to avoid the snags of the new treatment. 
Finally, there’s the question of measurable and unmeasurable. You can measure lots of things
like duration of remission, mortality and so on; what you can’t measure is the quality of life
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during these treatments and a whole lot of other things that should influence you in relation
to the treatment you are comparing, but they don’t enter the statisticians’ textbook.
Catovsky: I am not going to defend the statisticians, but I think they have changed over the
years since you left, Humphrey, because certainly quality of life is now part of all the studies.
Now the studies are so large, with thousands of patients, that they allow for many different
randomizations; so they can ask many questions – like we have seen yesterday in the MRC
review meeting [the annual review of the MRC Leukaemia Trials] – two or three or four
questions in the various trials, which are only possible because of the large number of
patients entering. I certainly do not necessarily always agree with the statisticians, but they
have improved. I also have to say that Richard Peto hasn’t been part of the MRC trials for
a long time. He now has a number of people who have been following the trials; some do
have a more open mind perhaps, more than they had early on.
Goldman: Ray, we are interested in your personal reminiscences of the allogeneic stem cell
transplant development over probably 25 years. If I may introduce the subject by referring
to a conversation I had in a bar with Ray Powles at the King David Hotel in Jerusalem in
1977, we both thought that the time had come to start formal allogeneic BMT for AML
patients in remission. Ray got it off the ground and I did not.
Powles: The UK has a long track record of innovative work in haemato-oncology. In my
own working lifetime, it has been interesting to see how my research started with an
immunotherapy slant, became very chemotherapy orientated, then BMT dominated the
picture, which has brought the whole circle once again, back to immunotherapy. 
First of all I can’t stress how important the initial Bart’s trials were, not only in devising
biological treatments but also in introducing the discipline of randomized trials in haemato-
oncology, and how important Derek was in bringing this discipline to our field. The
statistician involved was Malcolm Pike, who was very receptive to the nuances of leukaemia
and was also a wonderful character. 
An anecdote from this period was the naming of the ‘Concord’ trial. It had no ‘e’ as
compensation for having lost the battle for the naming of the aeroplane that did have an ‘e’.
Although this trial showed slight benefit, almost all the patients were dead in a year, which
were much worse results than for comparable patients who were also receiving CNS cranial
irradiation as prophylaxis.167 A disappointment with the Concord trial is that we did not
exactly repeat the method of immunotherapy used by Mathé; he used BCG
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scarification168 whereas in our trial, the BCG was given using a Heaf gun. We will never
know whether this explained the failure of this trial but the lesson to learn is, if you wish to
repeat a study which has shown efficacy, then it must be repeated exactly.
In my time with Mathé in Paris, at the end of 1968, I was very impressed with the fact that
he was already using intensive treatment, including BMT. He was an inspirational leader
and his haemato-oncology meetings in Paris every summer were legendary. Every day lunch
would be in the very smart Lebanese club; the menu was from a different region of France
and done with such exquisite style. 
We undertook four immunotherapy trials including the randomized study at Bart’s. There
were three other immunotherapy studies done worldwide in AML and all showed a trend
for benefit, particularly for survival after patients had relapsed.169
Goldman: But I think you were the first person to start routine allografting for leukaemia,
were you not?
Powles: In 1973 Professor Don Thomas in Seattle invited me to give a lecture on
immunotherapy because, at that time, they had already undertaken 100 matched sibling
allogeneic transplants, but only 11 patients had survived, with a large proportion of patients
dying because of recurrent disease, or due to the procedure. The recurrent disease was in
many respects because these were drug-resistant, heavily pre-treated relapsed patients. Don
had the vision to spot that an allogeneic transplant may be the perfect springboard for post-
transplant immunotherapy, an area that is very topical at the moment. Don, of course, won
the Nobel prize for his work. I was very impressed with the discipline of the Seattle unit
and, particularly, by the input of Rainer Storb. Rainer’s mother lived in Germany, so we
highjacked him into coming to our Sutton unit and transplanting one of our patients with
aplastic anaemia on one of his visits to his mother. We thus had our first success in 1973
followed in 1975 by our first successful transplant for acute leukaemia.170
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At that time blood cell separators also became available.171 Hamilton Fairley, through the
MRC, purchased the fourth separator in the world, the first in the UK, which we started
using for collecting leukaemia cells for use in immunotherapy at Sutton. It cost £30 000
then, which in today’s terms would probably be ten times this amount.  
Now let us go on to allografting. Cyclosporin has been an enormous benefit for preventing
GVHD following BMT and we at the Marsden were the first to develop its use. Although it
had shown considerable potential for use in kidney transplantation, it was not possible for
Professor Sir Roy Calne to use it for kidney patients because of its known nephrotoxicity.172
As a consequence we were able to first use it for patients receiving bone marrow transplants,
and show that its nephrotoxicity was reversible and could thus be used safely for kidney
transplants.173 We also showed that for BMT it could be used optimally in combination with
methotrexate and also in a mismatch transplant. To this end, using these methods, we even
managed to undertake a bone marrow transplant from father into leukaemic son and then,
after he was cured, the father developed leukaemia and we were able to transfer the son’s
marrow (now the surrogate father’s) back into the father. Both are cured 15 years later.174 
Immunotherapy has become topical again following the observation of John Goldman that
patients with CML, who after allogeneic BMT developed GVHD have less relapses than
those who do not have GVHD. We saw a similar observation in AML.
Concerning aciclovir. We were lucky to be able to have access to this drug to assess its
potential in treating herpes viruses at the end of the 1970s, quite a long time before it
became available in the USA. There was a problem with FDA approval, since it is a 
drug that interferes with DNA and they were concerned that it might do more harm 
than good.175
Goldman: I think we now should address the last issue of the day that is very important
and, of course, I refer to money. I think we have been lucky and I personally have been lucky
in having been associated with the LRF for almost the whole time that I was at the
Hammersmith. Gordon Piller was the brains behind the instigation of the LRF, but David
Grant is now very much in charge, and we have asked David to talk about funding of
leukaemia research in general and leukaemia therapy. As I have said already, much of what
we have talked about today wouldn’t have been possible without funding in general, and I
guess the LRF in particular. David, would you like to comment?
Dr David Grant: Thank you for the invitation. I am sure my illustrious predecessor,
Gordon, could speak far better than I on the first 30 years of the Fund, but I will be pleased
to comment on the last 11 years, while I have been associated with it. Out of interest, in
1961 the annual income of the LRF was £8000 and the research spend was £5000. In 2001
the income was £19 800 000 and the research spend was £21 100 000. We are the third-
largest national cancer charity. Obviously, leukaemia research is the paradigm for cancer
research, because the disease is so accessible; it’s so easy, well, straightforward to diagnose.
Response to treatment can be monitored fairly easily, and the paradigm of leukaemia
research, of course, is childhood leukaemia, as you have alluded to, in the spectacular success
of the MRC leukaemia trials. Therein, I think, lies the issue and the challenge for the future.
It was William Osler who said, ‘It’s much more important to treat the disease that the
patient has, rather than the patient with the disease’,176 and that we must aim to transfer all
the very intellectually clever and powerful science in the laboratory into clinical benefit. 
I want to touch on two issues. The first is the support from translational research, as it is
called now, and how we can achieve this. The second is the career structure in the UK that
at the moment is causing great concern for clinical scientists. As I said, obviously childhood
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leukaemia is the paradigm for leukaemia research and for cancer research to some some
extent; all cancer charities unashamedly use that as the success story, and of course we are
seduced by the spectacular success of the leukaemia trials. In fact, it was the trials and not
laboratory research that achieved that success. The overall survival rate hit 70 per cent in
1990, and to my knowledge in the last ten years that I have been with the Fund, it has
probably crept up to 75 per cent. The last 25 per cent stubbornly refuse to be cured, and
there are all sorts of reasons for that, which we are starting to unravel now. It’s vital, I think,
that one crucial role for the Fund is to integrate laboratory research with the clinical trials
that you have been discussing for the last half an hour or so, because there’s so much
information that can be gleaned from primary material that can then be fed back into
designing much more informed and directed trials and then to start to stratify patients.
Again from childhood leukaemia, the example is monitoring minimal residual disease by
molecular means, so that you can monitor tumour load in response to therapy, monitor
clearance kinetics and start to identify the good performers from the poor performers. The
spectacular success of cytogenetics that was commented on earlier in terms of patient
stratification, understanding the molecular basis of the way the drugs work and the basis of
relapse, is linked to genetic polymorphisms. All this is coming through now and should be
integrated into future trials. 
The other problem though, of course, is that you need the people to do that, and there has
been a concern in the last five years, in particular, with the introduction of new specialist
haematology training structures, that the clinical scientists of the future are not coming
through. I think it is one of the tasks of the Fund to put in a structured career path in the
UK for the outstanding young haematologists and oncologists who grow up with this
culture of bringing the laboratory-based knowledge through to well-designed and informed
clinical trials. 
Goldman: David, you certainly strike a very popular cord, because I feel that this is a major
problem that has developed over the last ten years. The training of clinical scientists that
seems to have been neglected by the National Health Service and Calman177 has also
unfortunately been neglected through the university grant mechanisms. Something needs
to be done, otherwise we will fall very far behind our colleagues in the developed world.
Gordon, do you want to comment particularly on the early days of the LRF on funding for
leukaemia research?
Piller: Yes, the LRF was set up in response to calls for what more could be done; this was
not a criticism of what was being done, but we established the Fund to be partners with the
clinicians and the scientists. To go back to what [Sir Lionel] Whitby was saying: when the
LRF was set up we instituted two rules. First, that you backed research on a pound-for-
pound basis, that means to say that you could then engage in long-term grant giving, simply
because you preserve your resources. Secondly we insisted that we would not succumb to
popular feelings at the time, the press etc., but that the Fund would be governed and
controlled. We then set up a Medical and Scientific Advisory Committee, which is still in
place today and it has been chaired by many famous people, including Sir John Dacie. It
started working with the professions and listening to what needed to be done, and then in
collaboration achieving their wish for better treatments and scientific approaches. The result
was, I think, that we set up our first professor when the LRF was just eight years old. He’s
a very distinguished gentleman who’s sitting just in front of me now [Frank Hayhoe]. We
also decided to support research in depth and to do two things: first to support clinical
research and set up clinical fellowships, and second to install units where they were required
and to support them. We came back to the best way to do this, by sticking to our principle
of financing research on a pound-for-pound basis, and with all legacies we adopted the
commonsense rule: if aunties or uncles were going to leave you something in the will, you
were not expected to go out and blow it. We had a strict rule that every legacy was invested,
and the Fund today has some £70 million to back Virchow’s wish in 1858 that, ‘I hope that
this disease, leukaemia, would eventually succumb and be cured’,178 and that’s our aim. 
Goldman: We are certainly moving in that direction, thanks in large part in this country to
the LRF. David, what about national policies for clinical care of patients with leukaemia?
Are we as a haematology community doing enough to encourage funding for clinical care
in the ward? 
Grant: As it happens, I hope that the National Cancer Research Network will certainly
focus minds. It is very interesting that the emphasis since I have been here has been very
much on the success of trials, the importance of trials and the continuity of trials – that it
is crucial that one trial leads on to another trial. Even in the haematology community,
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enough adult patients are still not entering trials, and that is a crucial omission and
something that certainly needs to be encouraged. 
Booth: I wonder if I can comment on a point that Gordon Piller made earlier. I think I
understood you to say that legacies were invariably invested and not spent. Is that correct?
I am very intrigued by that, because you must have had to deal with the charity
commissioners. As I have found in charitable foundations that I have been involved with,
charity commissioners insist that you spend your money and you don’t save it. How did you
get away with that?
Piller: Well, be tough with the charity commissioners! The answer is that all medical
research is there for the long term until other circumstances pertain. We would take the
view, and do take the view, that we need money year by year to cover all our present and
forward commitments; for all the grants from the LRF, once they are made, we have the
commitment to honour them. So we go back to the charity commissioners, who are not
experts in medical research, and argue our case. [Booth: I quite agree with that]. So that is
how we store it up. The subsidiary rule to investing money for charity is a very simple one
– your capital is only worth the income it produces – so you then have to work on the
income from that and from other fundraising to balance the books, but remembering that
if new approaches in medical and scientific research arise, we have the financial reserve to
respond and quickly. That’s the answer that we would give to the charity commissioners.
Booth: Obviously a very good policy. Well done.
Goldman: Any other points that people would like to bring up before we close? I think Tilli
would like to speak on behalf of the Wellcome Trust, but I would like to thank the people
who were invited to speak, those who have spoken, and the audience generally for being
very, very valuable and productive.
Tansey: Can I just echo those sentiments and thank you all very much for contributing to
this afternoon. Let me warn you that your endeavours are not over; we will be in touch with
you later, as we edit the transcript for publication. We will want more details from you all,
so you will be hearing from us quite a bit in the future. I would particularly like to thank
John Goldman for his excellent chairing this afternoon. It’s been a splendid occasion and I
hope you will now all join us in a glass of wine next door. 
Piller: On behalf of all of us here, may I thank the organizers, the Wellcome Trust and
contributors for providing such a splendid afternoon.
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azathioprine. Fox D M, Meldrum M, Rezak I.
(eds) (1990) Nobel Laureates in Medicine or
Physiology. New York, London: Garland Publishing,
Inc, 252–254. op. cit. notes 20 and 143.
Professor Victor Hoffbrand
DM FRCP FRCPath DSc (b. 1935) qualified from
the London Hospital and Oxford University in
1959. He worked at the Royal Postgraduate Medical
School, London, from 1962 until 1974, when he
was appointed Professor of Haematology at the
Royal Free Hospital School of Medicine. His
research was initially in megaloblastic anaemia and
subsequently in biochemical and molecular aspects
of leukaemia. He has also helped to develop an
orally active iron-chelating drug. He is, with Dr J E
Pettit, the author of Essential Haematology and
Clinical Atlas of Haematology and co-edits
Postgraduate Haematology.
Dr Peter Hunter
(b. 1938) qualified from Middlesex Hospital,
London, in 1963, and was Consultant Physician at
the Royal Shrewsbury Hospital, specializing in
endocrinology, from 1974 to 1993. From 1994 to
1997 he read Pharmacology at King’s College
London, as preparation for research on the history
of drug discovery in the modern era.
Professor Humphrey Kay
FRCP FRCPath (b. 1923) graduated from St
Thomas’s Hospital in 1945 and was in charge of
Haematology at the Royal Marsden Hospital,
London, from 1956 to 1984. From 1967 to 1984
he was Secretary to the MRC Committee on
Clinical Trials in Leukaemia and Co-ordinator of
the trials in childhood leukaemias.
Sir Ernest Kennaway
Kt FRS FRCP (1881–1958) qualified from the
Middlesex Hospital in 1907, was Demonstrator in
Physiology at Guy’s Hospital, London, from 1909
to 1914, and later chemical pathologist at the
Bland-Sutton Institute, Middlesex Hospital, from
1914 to 1921. In 1921 he joined the Research
Institute, Cancer Hospital, and was Director and
Professor of Experimental Pathology, from 1931 to
1946. He was Honorary Fellow of New College,
Oxford. See Cook J W. (1958) Ernest Laurence
Kennaway. Biographical Memoirs of Fellows of the
Royal Society 4: 139–154. See also Waller R E.
(1994) 60 years of chemical carcinogens: Sir
Ernest Kennaway in retirement. Journal of the
Royal Society of Medicine 87: 96–97.
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Professor Sir John Lilleyman
FRCP FRCPath FRCPCH (b. 1945) has been
Mark Ridgwell Professor of Paediatric Oncology at
St Bartholomew’s Hospital and The London
School of Medicine, Queen Mary, University of
London, since 1995. From 1975 to 1995 he was
Consultant Haematologist to the Children’s
Hospital, Sheffield, and from 1999 to 2002 was
President of the Royal College of Pathologists.
Professor Ian MacLennan
FRCP FRCPath FMedSci (b. 1939) has been
Professor of Immunology, since 1979, and
Director of the MRC Centre for Immune
Regulation, at the University of Birmingham since
1999. He was co-ordinator of the MRC trials in
multiple myeloma from 1980 to 1998 and was on
the Working Party on Leukaemia in Adults from
1982 to 1992.
Dr Gordon Piller
OBE FRCP(Ed) HonDVMS(Glas) HonFRCPCH
(b. 1925) was at Great Ormond Street Hospital for
Children, London, from 1952 and its House
Governor for ten years from 1960. He was a
Founder of the Leukaemia Research Fund in 1960
and was Director from 1970 to 1990. He has an
honorary fellowship at the Institute of Child Health
(University of London) and an Honorary Visiting
Research Fellowship at the University of Leeds.
Professor Raymond (Ray) Powles
CBE FRCP FRCPath (b. 1938) has been
Physician-in-Charge, since 1974, and Group
Head, Haemato-Oncology, since 1993, of the
Leukaemia and Myeloma Units at the Royal
Marsden Hospital. He has been Professor of
Haemato-Oncology at the University of London,
Institute of Cancer Research, since 1977, and
member of the MRC Working Party on
Leukaemia since 1974.
Professor Cornelius Rhoads
(1898–1959) was Chief, Medical Division of the
Chemical Warfare Service, from 1943 to 1945,
Director of the Sloan-Kettering Institute for
Cancer Research (1945), Scientific Director,
Memorial Center for Cancer and Allied Diseases
(1953), and Professor of Pathology, Department 
of Biology and Growth, Sloan-Kettering Division
of Cornell University Medical College (1952). 
See Rhoads C P. (1946) The sword and the
ploughshare. Journal of the Mount Sinai Hospital
13: 299–309. Anonymous. (1978) Cornelius
Packard Rhoads 1898–1959. CA: Cancer Journal
for Clinicians 28: 304–312.
Dr Rosemary Shannon 
FRCP FRCPCH (b. 1943) was appointed in 1980
to Leicester Royal Infirmary as a Consultant
Paediatric Oncologist after training in Glasgow
and Birmingham. She is a member of the United
Kingdom Children’s Cancer Study Group.
Dr John Stock
CChem FRSC (b. 1919) began his career as a
laboratory technician with British Cellophane Ltd,
in Bridgewater, Somerset, from 1938 to 1940.
After service in the Royal Air Force (1940–45), he
became a full-time London external degree student
at Portsmouth Technical College (now University
of Portsmouth) (1946–49). He held the 1949/50
Neil Arnott Postgraduate Studentship in
Chemistry, which he took up at the National
Institute for Medical Research in London, where
he worked on potential antitubercular compounds,
and for two further (MRC-financed) Studentship
years on the same topic. In 1952, he joined the
staff of the Institute of Cancer Research in London
(the Chester Beatty Laboratories), where he
synthesized potential tumour-inhibitory derivatives
of mainly amino acids, peptides and nucleosides.
He was Deputy Dean from 1983 to 1985 and
retired in 1986.
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Dr Tilli Tansey
HonMRCP (b. 1953) is Convenor of the History
of Twentieth Century Medicine Group and Reader
in the History of Modern Medical Sciences at the
Wellcome Trust Centre for the History of
Medicine, University College London. 
Professor John Walker-Smith
FRCP FRACP FRCPCH (b. 1936) was appointed
Consultant/Senior Lecturer in Child Health at
Bart’s and Queen Elizabeth Hospital for children in
1973, and became Professor of Paediatric
Gastroenterology in 1985. He transferred to the
Royal Free Hospital, London, in 1995 and spent a
sabbatical in History of Medicine with Dr Tilli
Tansey in 1993. He retired in October 2000, and
has been Emeritus Professor of Paediatric
Gastroenterology and Research Associate in the
History of Medicine since October 2000, and a
member of the History of Twentieth Century
Medicine Group since 1993.
Dr John Wilkinson
FRCP CChem FRSC (1897–1998) was
Consulting Haematologist at the United
Manchester Hospitals and Director of the
Department of Haematology, University and Royal
Infirmary of Manchester, from 1947 to 1962.
Together with Leslie Witts he founded the British
Society for Haematology, was President of the
European Society in 1959 and ‘life councillor and
founder’ of the International Society of Haematology.
See Black D. John Frederick Wilkinson. 
Munk’s Roll 11. www.rcplondon.ac.uk/scripts/ 
(site accessed 3 April 2003)
Dr Eve Wiltshaw 
OBE MD FRCP FRCOG (b. 1927) qualified in
1952 from the University of Wales and researched
clinical haematology in Boston, USA, from 1953
to 1955. She joined the Institute of Cancer
Research and Royal Marsden Hospital in 1955 to
work on drug treatment of cancer patients and was
Medical Director, from 1986 to 1994. She is best
known for the introduction of cisplatin and
carboplatin into clinical practice in the UK. See
Wiltshaw E. (1998) A History of the Royal Marsden
Hospital. London: Altman Publishing.
Professor Maxwell Wintrobe
FACP (1901–1986) was appointed Professor 
of Internal Medicine and Chairman of the
Department of Medicine at the University of Utah
College of Medicine in 1943. He directed the
Laboratory for the Study of Hereditary and
Metabolic Disorders from 1945 to 1973, and
served as Director of the Cardiovascular Research
and Training Institute from 1969 to 1973. He was
one of the pioneers of treatments for cancer
through chemotherapy. His many publications
include Wintrobe M M. (1980) Blood, Pure and
Eloquent. A Story of Discovery, of People, and of
Ideas. New York: McGraw-Hill. See Valentine 
W N. (1990) Maxwell Myer Wintrobe: October
27, 1901–December 9, 1996. Biographical
Memoirs of the National Academy of Sciences
59: 447–472.
Professor Leslie Witts
CBE FRCP (1898–1982) was Nuffield Professor
of Clinical Medicine at Oxford from 1938 to 1965
and Fellow of Magdalen College. From 1963 to
1968 he was a member of the Committee on
Safety of Drugs and Chairman of the
Subcommittee on Adverse Reactions. See Black D.
(1984) Leslie John Witts. Munk’s Roll 7: 618–620.
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Aciclovir (Zovirax) 
An antiviral used to treat shingles as well as 
the herpes simplex virus and other types of 
herpesvirus infections.
Acute lymphoblastic leukaemia (ALL)
(see lymphoblast) Acute leukaemia in which the
abnormal cells are almost totally blast forms of 
the lymphocytic series.
Acute myeloid (myeloblastic) leukaemia (AML)
(see myeloblast) A form of acute leukaemia in
which there are large numbers of myeloblasts
in the bone marrow.
Acute promyelocytic leukaemia (APML)
Acute leukaemia presenting as a severe bleeding
disorder with infiltration of the bone marrow by
abnormal promyelocytes and myelocytes, a low
plasma fibrinogen, and defective coagulation 
(also known as AML-FAB-M3).
ALL
See acute lymphoblastic leukaemia.
Aminopterin
A folic acid antagonist resulting in remission 
in ALL of children. op. cit. note 11.
AML
See acute myeloid leukaemia. 
APML
See acute promyelocytic leukaemia.
Azaserine
An antibiotic inhibitor of purine synthesis,
mutagenic and antitumorogenic. See notes 20 
and 143. 
Azathioprine (Imuran)
A derivative of 6-mercaptopurine used as an
immunosuppressive drug and in the treatment 
of leukaemia. 
Breakpoint cluster region (BCR)
The location within the BCR gene where DNA is
transected in chronic myeloid leukaemia.
Busulphan (Myleran)
An alkylating agent introduced for the treatment
of chronic myeloid leukaemia. Side effects include
bone marrow suppression and increased
pigmentation of the skin. 
CGL
See chronic granulocytic leukaemia.
Chemotherapy
The use of chemicals, especially drugs, in the
treatment of cancer.
Chronic granulocytic leukaemia (CGL)
A form of leukaemia characterized by an
uncontrolled proliferation of myeloid cells in the
bone marrow and in extramedullary sites, and the
presence of large numbers of immature and mature
granulocytic forms in various tissues and organs,
and in the circulating blood. Now more
commonly referred to as CML.
Chronic lymphocytic leukaemia (CLL)
A variety of leukaemia characterized by
lymphocytosis and an uncontrolled proliferation
and conspicuous enlargement of lymphoid tissue
at various sites such as lymph nodes, spleen and
bone marrow.
Chronic myeloid leukaemia (CML)
See CGL above.
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Chlorambucil
An alkylating drug that was introduced for the
treatment of chronic lymphocytic leukaemia.
CML progenitor cells
Immature cells present in the blood and bone
marrow in CML.
Cyclosporin A
An immunosuppressive agent commonly used in
organ transplantation. It inhibits - cell formation
and interleukin-2 production.
Daunorubicin
An antibiotic that interferes with DNA synthesis
and is used in the treatment of acute leukaemia. 
Folic acid
A B vitamin necessary for DNA and RNA
synthesis that allows the growth and reproduction
of cells. It helps in the formation of red blood cells.
Giemsa stain 
A mixture of methylene blue and eosin, used for
distinguishing different types of white blood cell
and for detecting parasitic microorganisms in blood
smears. It is one of the Romanowsky stains.
Gleevec or Glivec
Also known as imatinib or STI571. A new drug
for CML. See page 42.
Granulocyte
A white blood cell that, when stained with
Romanowsky stains, are seen to contain granules
in their cytoplasm. 
Granulocyte colony-stimulating factor (GCSF)
A cytokine that stimulates proliferation of
myeloid cells.
Haemopoietic stem cells
The most primitive blood-forming cell in the 
bone marrow.
Haemopoiesis
The process of formation and development 
of the various types of blood cells.
Imatinib 
See Gleevec, Glivec.
Leishmann stain
A neutral stain for blood smears devised by 
the British surgeon Sir William Leishmann
(1865–1926). It consists of a mixture of eosin 
(an acidic stain), and methylene blue (a basic stain)
in alcohol and is usually diluted and buffered
before use. It stains the different components of
blood in a range of shades between red and blue.
Leucapheresis
A procedure in which leucocytes are removed from
blood outside the body and the remaining blood is
retransfused into the donor.
Leucocyte
A white blood cell. Leucocytes are nucleated and
lack haemoglobin. They form part of the immune
system. See lymphocyte. 
Leukaemia
Any of a group of malignant diseases in which 
the bone marrow and other blood-forming organs
produce increased numbers of certain types of white
blood cells (leucocytes). It is classified by the
dominant cell type (for example ALL, AML, etc.)
and by duration from onset to death (acute or
chronic) if untreated. In ‘acute’ leukaemia, death
often ensued within a few months. It is associated
with acute symptoms such as severe anaemia,
haemorrhage and fever. The duration of ‘chronic’
leukaemia is measured in years, with graded 
onset of anemia or enlargement of spleen, liver 
or lymph nodes.
Lymphoblast
An early lymphocyte precursor present in the bone
marrow and blood in lymphoblastic leukaemia. 
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Lymphocyte
A type of white blood cell (leucocyte). They are
formed in the lymph nodes, bone marrow, spleen,
and provide about one-quarter of all circulating
leucocytes. They are important in the body’s
defence and are responsible for immune reactions.
There are two populations of lymphocytes: 
B lymphocytes, which produce circulating
antibodies and are responsible for humoral
immunity; and T lymphocytes, which are
responsible for cell-mediated immunity. 
May–Grünwald–Giemsa
A Romanowsky stain used for blood and bone
marrow films.
Megaloblastic anaemia
A form of anaemia caused by shortage of vitamin
B12 or folic acid.
Melphalan 
An alkylating drug used for the treatment 
of myeloma. 
6-mercaptopurine (6-MP)
An antineoplastic agent developed by Gertrude
Elion and George Hitchings. See pages 65 and 
67 and note 143.
Methotrexate
A variant of folic acid that interferes with cell
growth and is used to treat leukaemia. 
Myeloblast  
The earliest identifiable cell that gives rise to a
granulocyte, having a large nucleus and scanty
cytoplasm. It is normally found in the blood-
forming tissue of the bone marrow, but may
appear in the blood in a variety of diseases, most
notably in acute myeloblastic leukaemia (AML). 
Myeloma
Cancer of the plasma cells of the bone marrow. 
Myelopoiesis
Formation of leucocytes usually in the bone
marrow.
Nitrogen mustard
Compounds of the general formula 
R-N(CH2CH2Cl), used for their destructive
action upon lymphoid tissue in leukaemia,
Hodgkin's disease and other cancers.
Pancytopenia
Reduction in the number of erythrocytes, white
blood cells and platelets in circulating blood.
Platelet
Platelets are cells present in large numbers in blood
and play an important role in blood clotting.
Promyelocytic leukaemia
A form of AML characterized by propensity to
bleed excessively (also known as AML-FAB-M3).
Protooncogene
A gene involved in the regulation of normal cell
growth or proliferation and which when mutated
may induce malignancy.
Romanowsky stains
A group of stains used for microscopic
examination of blood cells. Romanowsky stains
give characteristic staining patterns, on the basis 
of which blood cells are classified, for example,
into neutrophils, eosinophils and basophils. The
group includes the stains of Leishmann, Wright
and May–Grünwald–Giemsa.
Sternberg lymphoma
A form of lymphoma present in the mediastinum
and involving cells of T lineiage.
STI571 (Imatinib)
See Gleevec.
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Terminal deoxynucleotidyl transferase
Terminal deoxynucleotidyl transferase (TdT) 
is an enzyme that catalyses the random addition 
of mononucleotides from dNTPs to the terminal 
3’-OH of a DNA initiator, accompanied by the
release of inorganic phosphate. The enzyme thus
provides a unique method for the labelling of 
the 3’ termini of DNA.
Vinblastine (Velbe)
A cytotoxic drug that is given by intravascular
injection mainly in the treatment of cancers of the
immune system, such as Hodgkin’s disease. It is
highly toxic, since it also acts on normal tissues;
common side effects include nausea, vomiting,
diarrhoea, and depression of bone marrow function.
Vinca alkaloids
A group of antimitotic drugs derived from the
Madagascar periwinkle (Vinca rosea – also called
Catharanthus roseus) that are used especially to
treat leukaemias and lymphomas. The group
includes vinblastine and vincristine.
Vincristine (Oncovin)
A cytotoxic drug with uses and side effects similar
to those of vinblastine.
Wright’s stain
Wright’s stain is one of the Romanowsky stains.
Leukaemia – Glossary
74
Leukaemia – Index
75
ABL protooncogene, 40–41
aciclovir, 61, 71
ACTH, 29, 44
acute leukaemias
chromosome abnormalities, 32
classification, 16, 31, 34, 36–37, 38, 72
diagnostic markers, 37–38
MRC trials, 53–54
see also acute lymphoblastic leukaemia; acute
myeloid leukaemia
acute lymphoblastic leukaemia (ALL), 16, 71
adult, 15
childhood see childhood acute lymphoblastic
leukaemia (ALL)
haematopoietic stem cell rescue, 19
T-cell (T-ALL), 35, 38, 39
acute myeloid leukaemia (AML), 16, 71
bone marrow transplantation, 58, 60
chemotherapy, 9, 15–16, 17, 53–54, 56–57, 71
childhood, 48
haematopoietic stem cell rescue, 19
immunotherapy, 17, 53, 58–59
M3 see acute promyelocytic leukaemia
M5 (acute monocytic leukaemia), 22
MRC trials, 53–54, 56–57
acute promyelocytic leukaemia (APML) (M3
AML), 16, 19, 37, 42, 71, 73
adrenocorticotrophic hormone (ACTH), 29, 44
agar, sloppy, 4
alkaline phosphatase anti-alkaline phosphatase
(APAAP) technique, 33
alkylating agents, 4–6, 7, 47
see also busulphan; chlorambucil; melphalan
ALL see acute lymphoblastic leukaemia
All-India Institute of Medical Sciences, New
Delhi, India, 20
all-trans-retinoic acid, 19, 42
alpha-interferon, 18, 41
American Society of Clinical Oncology (ASCO),
15, 42
amethopterin see methotrexate
AMGEN, 18
aminopterin, 7–8, 22, 43–44, 71
see also folic acid antagonists
AML see acute myeloid leukaemia
animal blood, transfusions using, 28, 29
Ann Arbor, Michigan, USA, 10
anthracycline, 15
see also daunorubicin
antibiotics, 28, 43, 51
antigens, cell surface, 33
antimetabolites, 7–9, 8–9
APML see acute promyelocytic leukaemia
arabinosyl cytosine see cytosine arabinoside
Argentina, 25, 34
arsenic, 10, 13, 20
ASCO (American Society of Clinical Oncology),
15, 42
Association of Clinical Pathologists, 10–11
Australia, 18, 19, 35
avidin–biotin peroxidase methods, 33
ayurvedic medicine, 20
azaserine, 9, 71
azathioprine, 9, 65, 67, 71
azure B, 30
Bart’s see St Bartholomew’s Hospital, London
B-cells, malignant, 35
BCG vaccine, 16–17, 26, 49, 58–59
BCR gene, 40, 71
BCR–ABL fusion gene, 41
blast cells, 35, 39, 45–46
bleeding, 27
blood cell separators, 60
Index: Subject
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blood transfusions, 27–29, 43, 50–51
BMT see bone marrow transplantation
bone marrow
aspiration biopsy, 52
failure (pancytopenia), 16, 21, 22–23, 73
toxicity (myelotoxicity), 57
bone marrow transplantation (BMT), 17–18, 19, 58
allogeneic, 18, 58, 59, 60
early, 22–23
HLA-matched, 18
mismatched, 18, 60
Bordetella pertussis, 16–17
Boston, Massachusetts, USA, 11, 23–24
breakpoint cluster region (BCR), 40, 71
British Journal of Haematology, 29
British Medical Journal, 35
Burroughs Wellcome, Tuckahoe, NY, USA, 48
busulphan, 5, 13–14, 20, 22–23, 71
butterfly cannulas, 27
Calman reforms, 62
Cambridge, UK, 10, 29, 30–31, 32
cancer research, 61, 62
cardiotoxicity, daunorubicin-induced, 15, 26
career structure, clinical scientists, 61–62
Catharanthus roseus, 14, 74
CB1348 see chlorambucil
CBRI see Chester Beatty Research Institute
CD3, 38
central nervous system (CNS), radiotherapy
(prophylaxis), 15, 26, 49, 58
central venous lines, 51
CGL, see chronic granulocytic leukaemia
charity commissioners, 64
Chemical Warfare Service, US, 11
Chemotherapy, 71
combination, 15–16, 45, 49, 56–57
early development, 4–6, 7–16, 44–48
intensification, 17, 49, 54
maintenance, 15, 45–46, 47, 52
myeloablative, 17, 18, 19
single agent, 14, 56
toxic effects, 15, 25–26, 45, 47, 50, 54–55, 57
vs radiotherapy, 21, 23
Chester Beatty Research Institute (CBRI),
London, 4–7, 10, 12, 14
see also Institute of Cancer Research
childhood acute lymphoblastic leukaemia (ALL),
42–48, 49–51, 52, 71
blood transfusions, 29, 43
boys vs girls, 47, 52
immunotherapy, 16–17, 46, 49
MRC (UKALL) trials, 46–48, 49, 51
pre-1948 treatment, 43
‘Total Therapy,’ 14–15, 45–46
childhood leukaemia, 42–43, 61
AML, 48
cure, 26–27
research needs, 62
T lymphoblastic (T-ALL), 35, 38, 39
Treatment-associated toxicity, 54
Children’s Cancer Group (CCG), USA, 47
China, 19
chlorambucil, 5, 10, 14, 72
chloramphenicol, 28
Christie Hospital, Manchester, 13, 20
chromosomes
abnormalities, 32–33, 37, 39–41, 50
number of human, 31
Philadelphia (Ph), 32, 39–41
translocations, 19, 32, 37
chronic granulocytic leukaemia (CGL), 23, 32, 39,
40, 71
see also chronic myeloid leukaemia
chronic leukaemias
classification, 31, 37, 71, 72
diagnostic tests, 38
see also chronic lymphocytic leukaemia; chronic
myeloid leukaemia
chronic lymphocytic leukaemia (CLL), 14, 34, 71
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classification, 31, 37, 72
haematopoietic stem cell rescue, 19
chronic myeloid leukaemia (CML), 71
alpha-interferon therapy, 18, 41
bone marrow transplantation, 18, 22–23, 60
classification, 31, 37, 71, 72
early chemotherapy, 10, 13–14
haematopoietic stem cell rescue, 19
patient treated in India, 19–20
Philadelphia (Ph) chromosome, 32, 39–41
progenitor cells, 41, 72
STI571 (imatinib) therapy, 42
Ciba Geigy, 41
classification of leukaemia, 16, 30–31, 34, 72
diagnostic markers, 35–36, 37–38
FAB group, 36–37, 38–39
clinical scientists, career structure, 61–62
clinical trials
future needs, 62, 63–64
MRC see Medical Research Council
randomized, 47–48, 57, 58
CLL see chronic lymphocytic leukaemia
CML see chronic myeloid leukaemia
CNS see central nervous system
colitis, paralytic, 25–26
combinatorial chemistry, 6
common ALL antigen, 33, 36
compliance, physicians with chemotherapy
protocols, 47, 51
Concord trial, 26, 46, 58–59
cortisone, 29, 44
co-trimoxazole (Septrin), 51
CRC Centre for Cancer Therapeutics, 6
cure, 26–27
cyclophosphamide, 57
cyclosporin A, 60, 72
see also nephrotoxicity
cytarabine see cytosine arabinoside
cytochemistry, 31, 34, 36
cytogenetics, 31–33, 37, 39–41, 50, 62
cytosine arabinoside (cytarabine), 15, 16, 53, 54
DAT chemotherapy regimens, 53–54
daunorubicin (daunomycin), 15, 16, 26, 72
in DAT regimens, 53, 54
Delhi, India, 19–20
deoxynucleotide triphosphates, 37
Department of Health and Social Security
(DHSS), 53
Detroit, Michigan, USA, 8–9
Duke University, Durham, North Carolina, USA, 21
Edinburgh, 12, 39–40, 50
electron microscopy, 34
encephalitis, 54
eosin Y, 30
erythrocyte rosettes, sheep, 35, 36
erythromycin, 28
ethyl carbamate (urethane), 13, 20–21
FAB (French–American–British) group, 36–37,
38–39
FDA (Food and Drug Administration), 42, 61
fluorescence in situ hybridization (FISH), 32–33
folic acid, 8, 72
antagonists, 7–8, 22, 29, 44
see also aminopterin
Food and Drug Administration (FDA), 42, 61
France, 15, 26, 33, 36, 40, 46, 59
French–American–British (FAB) group, 36–37,
38–39
funding
leukaemia research and therapy, 48–49, 53,
61–64
National Health Service, 50–51, 53
G-CSF, see granulocyte colony-stimulating factor
gender differences, response to therapy, 47, 52
Germany (including West Germany), 46, 47, 49, 59
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Giemsa banding (stain), 32, 72
Glasgow, 50
Gleevec, Glivec (STI571, imatinib), 40, 41–42,
44, 72
GM-CSF, see granulocyte-macrophage colony-
stimulating factor
graft-versus-host disease (GVHD), 17–18, 60
graft-versus-leukaemia reaction, 18
granulocyte, 19, 72
granulocyte colony-stimulating factor (G-CSF),
18, 19, 72
granulocyte-macrophage colony-stimulating factor
(GM-CSF), 18
Great Ormond Street Hospital for Sick Children,
London, 29, 31, 52
growth factors, haemopoietic, 18, 19
GVHD see graft-versus-host disease
‘Haddow’ phenomenon, 5
haematology, laboratory vs clinical, 24–25
haemopoiesis, 72
haemopoietic growth factors, 18, 19
haemopoietic stem cells, 19, 72
haemorrhage, 27
Hammersmith Hospital, London, 3, 21, 22, 23,
24–25, 34–35, 37, 39
Henry Ford Hospital, Detroit, Michigan, 8–9
herpes viruses, 61
Heyl stain, 30
HN2 (nitrogen mustard), 6, 10, 11, 12, 73
Hodgkin’s disease, 10, 15–16
Houston, Texas, USA, 16
imatinib (STI571), 40, 41–42, 44, 72
immunological techniques, 33, 34, 35, 36
immunotherapy, 26, 58–60
in AML, 17, 53, 58–59
in childhood ALL, 16–17, 46, 49
post-transplant, 59, 60
Imperial College School of Medicine,
Hammersmith Hospital, London, 3
Imuran (azathioprine), 9, 65, 67, 71
India, 19–20
infections, 28
Institute of Cancer Research, Royal Cancer
Hospital, London, 4, 6, 23–24
see also Chester Beatty Research Institute; Royal
Cancer Hospital
alpha-interferon, 18, 41
intravenous drips, 25, 27
kidney transplantation, 60
King’s College Hospital, London, 31
Lady Tata Memorial Hospital, Mumbai, India, 20
Lancet, 9, 35, 43
Leishmann stain, 30, 72
leucapheresis, 60, 72
leucocyte, 72
leukaemia, definition, 72
Leukaemia: Research and Clinical Practice
(Hayhoe 1960), 34
leukaemia cells, 50
detection of residual, 38
irradiated, 16–17, 49
morphology, 30–41
origin and nature, 38
Leukaemia Research Fund (LRF), 18, 19–20, 61–64
Centre for Adult Leukaemia, 3
Leukaemia Unit, MRC, 3–4, 25
Leukemia and Allied Disorders (Forkner 1938), 30
LRF see Leukaemia Research Fund
lymphoblast, 72
see also ALL, blast cells
lymphocyte, 35, 38, 73
lymphoid leukaemias, 35–36
see also acute lymphoblastic leukaemia; chronic
lymphocytic leukaemia
lymphoma, 23
Sternberg (T lymphoblastic
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leukaemia/lymphoma), 35, 39, 73
see also Hodgkin’s disease
maintenance treatment, 14, 45–46, 47, 52
Manchester, 12, 13, 18, 20, 52
‘Manchester drug,’ 21
Manchester Royal Infirmary, Manchester, 13
Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA, 41
May–Grünwald–Giemsa stain, 30, 73
measles (and measles vaccine), 52, 54
Medical Research Council (MRC)
Cancer Committee, 55
clinical trials, 16, 23, 51, 53–59
annual review, 58
childhood ALL (UKALL), 46–48, 49, 51
Concord trial, 26, 46, 58–59
myeloma, 35, 54–55, 56, 57
Cytogenetics Group, 39–40
financial support, 53
Leukaemia Unit, 3–4, 25
Leukaemia Working Parties, 23, 30–31, 46, 48,
53, 55
megaloblastic anaemia, 37, 73
Melbourne, Australia, 18, 19
melphalan, 5, 6, 14, 57, 73
Memorial Hospital, New York, 16
6-mercaptopurine (6-MP), 9, 14, 44, 49, 56, 73
discovery, 48
maintenance therapy, 15, 52
methotrexate, 8, 49, 73
bone marrow transplantation and, 60
maintenance therapy, 15, 45, 52
toxicity, 45, 50
Middlesex Hospital, London, 28
minimal residual disease (MRD), 38, 62
molecular biology, 18, 32–33, 42
monoclonal antibodies, 33, 34
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